GB2276161A - Aniline and benzanilide derivatives - Google Patents

Aniline and benzanilide derivatives Download PDF

Info

Publication number
GB2276161A
GB2276161A GB9305468A GB9305468A GB2276161A GB 2276161 A GB2276161 A GB 2276161A GB 9305468 A GB9305468 A GB 9305468A GB 9305468 A GB9305468 A GB 9305468A GB 2276161 A GB2276161 A GB 2276161A
Authority
GB
United Kingdom
Prior art keywords
group
title compound
evaporated
give
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9305468A
Other versions
GB9305468D0 (en
Inventor
William Leonard Mitchell
John Bradshaw
John Watson Clitherow
Malcolm Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB9305468A priority Critical patent/GB2276161A/en
Publication of GB9305468D0 publication Critical patent/GB9305468D0/en
Publication of GB2276161A publication Critical patent/GB2276161A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings

Abstract

Compounds of the general formula (I): <IMAGE> and physiologically acceptable salts or solvates thereof, in which the symbols are as defined in the specification, are 5-HT1D antagonists useful for the treatment of CN disorders, endocrine disorders and sexual dysfunction.

Description

CHEMICAL COMPOUNDS This invention relates to novel aniline and benzanilide derivatives, to processes for their preparation, and to pharmaceutical compositions containing them.
According to the present invention there is provided compounds of the general formula (I) :
or a physiologically acceptable salt or solvate thereof, in which R' represents a hydrogen atom or a halogen atom or a C1lkyl or C, 6alkoxy group; R2 and R3, which may be the same or different, each independently represent a hydrogen atom or a halogen atom, or C1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, hydroxy, -CF3, -CN, -NO2, -CO2R10, -COR6, -SR6, -SOR6, -SO2R6, -CR6=NOR', -CONR6R7, -CONR6SO2R7, -CONR6(CH2)mCO2R7, -CONR6(CH2)mOC1-4alkyl, -SO2NR6R7, -OC(O)NR6R7, -(CH2)nNR8R9, -(CH2)nOC(O)C1-4alkyl (optionally substituted by a C1-6alkoxy group), or C, 4alkoxyalkyl (optionally substituted by a C1 4alkoxy or hydroxy group);; or R represents a 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,5-oxadiazol-3-yl, imidazol-1-ylmethyl, dioxolan or thioxolan group, each of which may be optionally substituted by a C1-3alkyl group; or, when R2 and R3 are attached to adjacent carbon atoms, they may form a 5- or 6-membered saturated fused ring which contains one or two oxygen atoms and which may be optionally substituted by an oxo group; R4 and R5, which may be the same or different, each independently represent a hydrogen atom or a halogen atom, or a hydroxy, C1-6alkoxy or C1-6alkyl group; R6, R7 and R8 which may be the same or different, each independently represent a hydrogen atom or a C1-6alkyl group; or -NR6R7 forms a saturated heterocyclic ring which has 5 or 6 ring members which, when there are 6 ring members, may optionally contain in the ring one oxygen or sulphur atom; R9 represents a hydrogen atom or a C1-6alkyl, -COR'3 or -SO2R'4group; or -NR8R9 forms a saturated heterocyclic ring which has 5 or 6 ring members, may optionally be substituted by an oxo group and, when there are 6 ring members, may optionally contain in the ring one oxygen or sulphur atom; R10 represents a hydrogen atom or a C1 alkyl group optionally substituted by one or two substituents selected from C1alkyl, Cl 6alkoxy, hydroxy or -NR6R7; R and Rl2, which may be the same or different, each independently represent a hydrogen atom or a C1 6alkyl group;; Rl3 represents a hydrogen atom or a group selected from Cl6alkyl, C1alkoxy or a Cl4alkoxyalkyl group; Rl4 represents a C1alkyl or phenyl group; X represents -COHN-, -NHCO-, -CH2NH- or -NHCH2-; m represents an integer from 1 to 3; n represents zero or an integer from 1 to 3; and p represents an integer from 2 to 4.
It is to be understood that the present invention encompasses all geometric and optical isomers of the compounds of general formula (I) and their mixtures including the racemic mixtures thereof.
Physiologically acceptable salts ofthe compounds formula (I) include acid addition salts formed with inorganic or organic acids (for example hydrochlorides, hydrobromides, sulphates, phosphates, benzoates, naphthoates, hydroxynaphthoates, ptoluenesulphonates, methanesulphonates, sulphamates, ascorbates, tartrates, citrates, oxalates, maleates, salicylates, fumarates, succinates, lactates, glutarates, glutaconates, acetates or tricarballylates) and, where appropriate, inorganic base salts such as alkali metal salts (for example sodium salts).
In the compounds of formula (I), the term "Cl4alkyl" or "C1 6alkoxy" as a group or part of a group means that the group is straight or branched and consists of 1 to 6 carbon atoms. Examples of suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy. The term "halogen" within the definition of R2 means fluorine, chlorine, bromine or iodine.
Within the above definition, when R2 and R3 are attached to adjacent carbon atoms and together form a 5- or 6-membered saturated fused ring which contains one or two oxygen atoms and which may be optionally substituted by an oxo group, suitable groups represented by -R2-R3- include -C(O)OCH2-, -OCH2O- or -CH2OCH2O-.
Within the above definition, when -NR6R7 or -NR8R9 represent a saturated heterocyclic ring, these contain 5 or 6 ring members, one of which (when there are 6 ring members) may be an oxygen or a sulphur atom. Suitable heterocyclic groups are a pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl group.
Where a saturated heterocyclic ring is formed by the group -NR8R9 and said ring is substituted by an oxo group, suitable heterocyclic groups include a 2-oxo-1-pyrrolidinyl, 4-oxo-3 -thiazolidinyl or 2-oxo-tetrahydro-1,3-thiazinyl group.
The phenyl ring B may preferably be attached in the meta or more particularly the para position of the phenyl ring A relative to the group X.
When the phenol ring B is substituted by a single atom or group as defined above the substituent is preferably attached in a position meta or para to the phenyl ring A in general formula (I). When the phenyl ring B is substituted by two atoms or groups as defined above one substituent is preferably attached in the position para to, and the other is in a position ortho to the phenyl ring A in general formula (I).
A preferred group of compounds of general formula (I) is that wherein the phenyl ring B is substituted by one or two substituents as defined in general formula (I) wherein one substituent is in the position para to the phenyl ring A in general formula (I) the second substituent is in the position ortho to the phenyl ring A in general formula (I).
Another preferred group of compounds of general formula (I) is that wherein the phenyl ring B is substituted by a single substituent as defined in general formula (I) wherein said substituent is in the position para to the phenyl ring A in general formula (I).
A further preferred group of compounds of general formula (I) is that wherein R2 and R3 each independently represent a hydrogen atom or a halogen atom; or a C1 6alkyl, especially methyl, group; hydroxymethyl; hydroxy; -CN; -CO2R1 where Rl is a C,4alkyl, especially methyl or ethyl, group optionally substituted by a C,4alkoxy, especially methoxy, group; -COR6 where R6 is a Cl4alkyl, especially methyl, ethyl, propyl or butyl, group; -SR6 where R6 is a C,4alkyl, especially methyl, group; -SOR6 where R6 is a Cl4alkyl, especially methyl, group; -CR6=NOR7 where R6 is a hydrogen atom or a C,4alkyl, especially methyl, group, and R7 is a hydrogen atom or a C1-6alkyl, especially methyl, group; -CONR6R7 where R6 and R7 each independently represent C,6alkyl, especially methyl, groups or -NR6R7 forms a saturated heterocyclic group which has six members and contains in the ring one oxygen atom, especially a morpholinyl ring; -CONR6(CH2)mOC1-4alkyl, where R6 is a Cl4alkyl, especially methyl, group and m is two, especially the group -CON(CH3)(CH2)2OCH3; -SO2NR6R7 where R6 and R7 each independently represent a hydrogen atom or a C,4alkyl, especially methyl, group; -OC(O)NR6R7 where R6 and R7 each independently represent a Cl4alkyl, especially methyl, group; -(CH2)nNR8R9 where R8 is a hydrogen atom or a Cl4alkyl, especially methyl, group, R9 is a C1-6alkyl, especially methyl, group, or -COR (where R'3 is a C1-6alkyl, especially methyl, group, a C,4alkoxy, especially methoxy or ethoxy, group or a C1-4alkoxyalkyl, especially methoxymethyl, group) or -SO2Rl4 (where R'4 is a C,4alkyl, especially methyl, group), or -NR8R9 forms a saturated heterocyclic group which has six ring members and contains in the ring one oxygen or sulphur atom, especially a morpholinyl, thiomorpholinyl or 2-oxo-1-pyrrolidinyl ring, and n is zero, 1 or 2; or a C14alkoxyalkyl, especially methoxymethyl or methoxyethyl, group substituted by a C14alkoxy, especially methoxy, group.
Another preferred group of compounds of general formula (I) is that wherein R2 represents a hydrogen atom, a chlorine atom or a methyl group and R3 represents hydroxymethyl, hydroxy, -CO2CH2CH2OCH3, -COCH3, -SOCH3, -C(CH3)=NOH, -CON(CH3)2, -SO2NH2, -SO2NHCH3, -SO2N(CH3)2, -OC(O)N(CH3)2, -NHCH3, -N(CH3)2, -N(CH3)COCH3, -CH2NHCO2CH2CH3, -CH2N(CH3)COCH20CH3, -NHSO2CH3,
Also preferred is the group of compounds of general formula (I) wherein R is a hydrogen atom or a C,4alkyl, especially methyl, group.
Another preferred group of compounds of general formula (I) is that wherein R' is attached at a position ortho to the phenyl ring B on the phenyl ring A in general formula (I).
Another preferred group of compounds of general formula (I) is that wherein R4 is attached in the para-position relative to the group X.
A further preferred group of compounds of general formula (I) is that wherein R4 is a halogen atom, especially a fluorine or chlorine atom, or a hydroxy or C,6alkoxy, especially methoxy, group.
Also preferred is the group of compounds of general formula (I) wherein R5 is a hydrogen atom or a fluorine atom.
A yet further preferred group of compounds of general formula (I) is that wherein R" and Rl2 each represent a C,4alkyl, especially methyl, group.
Also preferred is the group of compounds of general formula (I) in which X is -NHCO- or -CONH-.
Another preferred group of compounds of general formula (I) is that wherein p is 3.
Preferred compounds of general formula (I) include: 4'-[[3-[3-(dimethylamino)propyl]-4-methoxybenzoyl]amino][1,1-biphenyl]-4carboxylic acid; 3-[3-(dimethylamino)propyl]-N-[4'-(1-hydroxyethyl)[1,1'-biphenyl]-4-yl] -4-methoxybenzamide; N-[4'-(aminosulphonyl)[ 1,1 '-biphenyl]4-yl]-3 -[3 -(dimethylamino)propyl]-4methoxybenzamide; 3 -[3 -(dimethylamino)propyl]-N-[4'-(hydroxymethyl)E 1,1 '-biphenyl]-4-yl] -4-methoxybenzamide; N-[[4'-[[3-[3-(dimethylamino)propyl]-4-methoxybenzoyl] amino] [1,1 '-biphenyl]-4-yl] carbonyl]glycine; 3-[3-(dimethylamino)propyl]-N-[4'-(hydroxymethyl)-2,2'-dimethyl[1,1'-biphenyl]-4-yl] -4-methoxybenzamide; 3 -[3 -(dimethylamino)propyl]-N-[4'-(hydroxymethyl)-2'-methylE 1,1 '-biphenyl] -4-yl] -4-methoxybenzamide; 4'-[[3-[3-(dimethylamino)propyl]-4-hydroxybenzoyl]amino][1,1'-biphenyl] -4-carboxamide; 3-[3-(dimethylamino)propyl]-N-(4'-hydroxy-2-methyl[1,1'-biphenyl]-4-yl) -4-methoxybenzamide; N-[4-(3-oxa-1H-isobenzofuran-6-yl)phenyl]-3-[3-(dimethylamino)propyl]-4methoxybenzamide; 3-[3-(dimethylamino)propyl]-N-[4'-(1H-imidazol-1 -ylmethyl)[1, 1 '-biphenyl]A-ylJA- methoxybenzamide; and their physiologically acceptable salts and solvates.
Particularly preferred compounds of general formula (I) include: N-(4'-acetyl[1,1'-biphenyl]-4-yl)-3-[3-(dimethylamino)propyl]-4-methoxybenzamide; 4'-[[3 -[3 -(dimethylamino)propyl] -4-methoxybenzoyl] amino] C 1 , 1 '-biphenyl] -4-carboxamide; 4'-[[3-[3-(dimethylamino)propyl]-4-methoxybenzoyl]amino]-3 -hydroxy [1,1'-biphenyl]-4-carboxylic acid; 3 -[3-(dimethylamino)propyl]-N-(4'-hydroxy[ 1,1 '-biphenyl]-4-yl)-4- methoxybenzamide; 4'-[[3-[3-(dimethylamino)propyl]-4-methoxybenzoyl]amino]-2-methyl[1,1'-biphenyl]-4carboxylic acid; N-(2'-chloro-4'-formyl[1,1'-biphenyl]-4-yl)-3-[3-(dimethylamino)propyl] -4-methoxybenzamide; 3 -[3 (dimethylamino)propyl]-N-(4'-formyl-2'-methyl [1,1 '-biphenyl]-4-yl) -4-hydroxybenzamide; N-(4'-acetyl-2'-methyl[1,1'-biphenyl]-4-yl)-3-[3-(dimethylamino)propyl]-4methoxybenzamide; 3-[3-(dimethylamino)propyl]-N-[4'-formyl[1,1'-biphenyl]-4-yl)-4-methoxybenzamide; (+/-)-[4'-[[3 -[3 -(dimethylamino)propyl] -4-methxybenzoyl] amino] -3 -methylC 1,1'- biphenyl]-4-yl]methyl 2-methoxypropanoate; and their physiologically acceptable salts and solvates.
5-Hydroxytryptamine (serotonin) is a neurotransmitter which is widely distributed within the central nervous system (CNS), platelets and the gastrointestinal tract. Changes in transmission in serotonergic pathways in the CNS are known to modify, for example, mood, psychomotor activity, appetite, memory and blood pressure. Release of 5-hydroxytryptamine from platelets can mediate vasospasm while changes in free 5-hydroxytryptamine levels in the gastrointestinal tract can model secretion and motility.
Abundant pharmacological studies have led to the discovery of multiple types of receptors for 5-hydroxytryptamine, thus providing a molecular basis to the diversity of its actions. These receptors are classed as 5-HT1, 5-HT2 and 5-HT3, with 5-HT, receptors being sub-classified as 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D and 5-HT1D(like) receptors. The identification of these classes and sub-classes of receptor is based mainly on radioligand binding studies.
Compounds having a selective antagonist action at 5-HTlD receptors such as those described herein may exhibit a beneficial effect on subjects suffering from CNS disorders.
In the present specification, a 5-HT,D antagonist is a non-naturally occurring (synthetic) compound that specifically and selectively antagonises 5-HT,D receptors, i.e.
blocks the specific actions of 5-hydroxytryptamine mediated by 5-HT,D receptors. Such compounds may be identified by a high level of affinity (pKi > 8) in the in vitro human cortex and guinea-pig striatum radioligand binding assays described by Hoyer et al, Neuroscience Letters, 1988, 85, p357-362. Activity at 5-HT,D receptors may be confirmed in vivo using the guinea pig rotation model described by G A Higgins et al, Br.
J. Pharmacol., 1991, 102, p305-310.
The affinity of a compound for 5-HT,A, 5-HT,C and/or 5-HT2 receptors is measured using the in vitro tests described in the following publications: 5-HT,A Gozlan et al, Nature, 1983 305, p140-142 5-HT,c Pazos et al, Eur. J.Pharmacol., 1984, 106, p531-538 5-HT2 Humphrey et al, Br. J. Pharmacol 1988, 94, pl 123-1132 (rabbit aorta model).
Thus, for example, compounds of the present invention have been shown to inhibit 5-hydroxytryptamine induced contraction of the dog isolated saphenous vein and to antagonise the 5-hydroxytryptamine induced inhibition of neurotransmission in central and peripheral neurones.
5-HT,D antagonists, and in particular the compounds of the present invention, may therefore be of use in the treatment of CNS disorders such as mood disorders, including depression, seasonal affective disorder and dysthymia; anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnestic disorders and age-associated memory impairment; and disorders of eating behaviour, including anorexia nervosa and bulimia nervosa. Other CNS disorders include Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.
5-HT1D antagonists, and in particular compounds of the present invention, may also be of use in the treatment of endocrine disorders such as hyperprolactinaemia, the treatment of vasospasm (particularly in the cerebral vasculature) and hypertension, as well as disorders in the gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual dysfunction.
Therefore, according to a second aspect of the invention, we provide a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in therapy.
According to a further aspect of the present invention, we therefore provide a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.
According to another aspect of the invention, we provide the use of a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for the manufacture of a therapeutic agent for the treatment of the aforementioned disorders.
According to a further aspect of the invention, we provide, a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a physiologically acceptable salt or solvate thereof.
In particular, according to another aspect of the present invention, we provide a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.
It will be appreciated that the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents such as tricyclic antidepressants (e.g.
amitriptyline, dothiepin, doxepin, trimipramine, butriptyline, clomipramine, desipramine, imipramine, iprindole, lofepramine, nortriptyline or protriptyline), monoamine oxidase inhibitors (e.g. isocarboxazid, phenelzine or tranylcyclopramine) or 5-HT reuptake inhibitors (e.g. fluvoxamine, sertraline, fluoxetine or paroxetine), and/or antiparkinsonian agents such as dopaminergic antiparkinsonian agents (e.g. levodopa, preferably in combination with a peripheral decarboxylase inhibitor e.g. benserazide or carbidopa), or a dopamine agonist (e.g. bromocriptine, lysuride or pergolide). It is to be understood that the present invention covers the use of a compound of general formula (I) or a physiologically acceptable salt or solvate thereof in combination with one or more other therapeutic agents.
Thus there is provided in a further or alternative aspect of the present invention a compound of general formula (I) or a physiologically acceptable salt or solvate thereof and an antidepressant agent in the presence of each other in the human or non-human animal body for use in the treatment of the aforementioned disorders.
While it is possible that a compound of general formula (I) may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical formulation.
The compounds of general formula (I) and their physiologically acceptable salts and solvates may be formulated for administration in any convenient way, and the invention therefore also includes within its scope pharmaceutical compositions comprising at least one compound of general formula (I) or a physiologically acceptable salt or solvate thereof. Such compositions may be presented for use in à conventional manner in admixture with one or more physiologically acceptable carriers or excipients.
The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
Thus, the compositions according to the invention may be formulated for oral, buccal, parenteral or rectal administration or in a form suitable for administration by inhalation or insufflation. Oral administration is preferred.
Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone; fillers, for example, lactose, sugar, microcrystalline cellulose maize-starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch or sodium starch glycollate; or wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methylcellulose, glucose/sugar syrup, gelatin, hydroxypropyl methylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; and preservatives, for example, methyl or propyl p-hydroxybenzoates or sorbic acid. The compositions may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.
The composition according to the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dose form in ampoules, or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
For administration by inhalation either orally or nasally the compositions according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas, or from a nebuliser. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.
Alternatively, for administration by inhalation the compositions according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges of e.g. gelatin, or blister packs from which the powder may be administered with the aid of an inhaler or insufflator.
The pharmaceutical formulations according to the invention may also contain other active ingredients such as antimicrobial agents, or preservatives.
The compositions according to the invention may be prepared by mixing the various ingredients using conventional means.
It will be appreciated that the amount of a compound of general formula (I) required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or veterinarian. In general, however, a proposed dose of the compounds of the invention for administration in man is 0.5 to 1000mg, preferably 1 to 200mg ofthe active ingredient per unit dose which could be administered, for example, l to 4 times per day.
The compounds of the invention may be prepared by a number of processes as described in the following. In describing the processes which may be used for preparing the compounds of general formula (I) or intermediates useful in the preparation thereof; any of R'-RI4, m and n in the various formulae are as defined in general formula (I) unless otherwise stated.
It will be appreciated that in the following methods for the preparation of compounds of general formula (I), for certain reaction steps it may be necessary to protect various reactive substituents in the starting materials for a particular reaction and subsequently to remove the protecting group. Such protection and subsequent deprotection may be particularly pertinent where R6, R7, RS, R9, R , R11 and/or Rl2 in intermediates used to prepare compounds of general formula (I) are hydrogen atoms. Standard protection and deprotection procedures can be employed, for example formation of a phthalimide (in the case of a primary amine), benzyl, trityl, benzyloxycarbonyl or trichloroethoxycarbonyl derivatives.Subsequent removal of the protecting group is achieved by conventional procedures. Thus a phthalimide group may be removed by treatment with hydrazine or a primary amine, for example methylamine. Benzyl or benzyloxycarbonyl groups may be removed by hydrogenolysis in the presence of a catalyst e.g. palladium, and trichloroethoxycarbonyl derivatives may be removed by treatment with zinc dust. Trityl groups may be removed under acidic conditions using standard procedures.
It may also be necessary in some cases to protect carboxylic acid groups (e.g. as esters) or aldehyde or ketone groups (e.g. as acyclic or cyclic acetals or ketals or as thioacetals or thioketals). Subsequent removal of these protecting groups is achieved by conventional procedures. Thus for example alkyl esters may be removed under conditions of acidic or basic hydrolysis, benzyl esters may be removed by hydrogenolysis in the presence of a catalyst e.g. palladium. Acyclic or cyclic acetals or ketals may be removed under conditions of acidic hydrolysis and thioacetals and thioketals may be removed using a mercuric salt.
Hydroxyl groups may also need protection and these may be adequately protected under amenable conditions as their esters or trialkylsilyl, tetrahydropyran and benzyl ethers. Such derivatives may be deprotected by standard procedures.
According to one general process (1A), the compounds of general formula (I) in which X represents the group -CONH-, may be prepared by a carbonylation reaction involving an aniline (11)
(where R4, R5, R1', R12 and p are as defined in general formula (I)) and a halophenyl compound (Ill)
(where Rl, R2 and R3 are as defined in general formula (I) and Y is a bromine or iodine atom or the group -OSO2CF3).
Alternatively, according to the general process (it), the compounds of general formula (I), in which X represents the group -NHCO-, may be prepared by a carbonylation reaction involving a halophenyl compound (IV)
(where R4, R5, R", R12 and p are as defined in general formula (I) and Y represents a bromine or iodine atom or the group -OSO2CF3) and an aniline of formula (V)
(where R', R2 and R3 are as defined in general formula (I)).
Both reactions take place, for example, in the presence of carbon monoxide using a palladium salt as a catalyst. The reaction is effected in the presence of a suitable base e.g.
a trialkylamine such as triethylamine or tri-n-butylamine and may be conducted in a suitable solvent such as an amide e.g. dimethylformamide or a nitrile e.g. acetonitrile at a temperature within the range of-100C to +1500C.
Suitable palladium salts for the reaction include triarylphosphine palladium (II) salts such as bis(triphenylphosphine)palladium (II) chloride.
According to another general process (2A), the compounds of general formula (I), in which X represents the group -CONH-, may be prepared by reacting an aniline of formula (II) with an activated carboxylic acid derivative of formula (V1)
(where Z is a leaving group).
Alternatively, according to the general process (2B), the compounds of general formula (I), in which X represents the group -NHCO-, may be prepared by reacting an aniline of formula (V) with an activated carboxylic acid derivative of formula (VII)
(where Z is a leaving group).
Suitable activated carboxylic acid derivatives represented in formulae (VI) and (VII) include acyl halides (e.g. acid chlorides) and acid anhydrides including mixed anhydrides.
These activated derivatives may be formed from the corresponding acids of formulae (VIII) or (IX)
respectively, by well known procedures. For example, acid chlorides may be prepared by reaction with phosphorus pentachloride, thionyl chloride or oxalyl chloride and acid anhydrides may be prepared by reaction with an appropriate acid anhydride (e.g.
trifluoroacetic anhydride), an acid chloride (e.g. acetyl chloride), an alkyl or aralkyl haloformate (e.g. ethyl or benzyl chloroformate) or methanesulphonyl chloride.
Activated carboxylic acid derivatives of formulae (VI) and (VII) may also be prepared in situ by the reaction of the corresponding acids of formulae (VIII) and (IX), respectively, with a coupling reagent such as 1,1 '-carbonyldiimidazole, dicyclohexylcarbodiimide or diphenylphosphorylazide.
The conditions under which the activated carboxylic acid derivatives of formulae (VI) and (VII) are formed and subsequently reacted with the anilines of formulae (II) and (V), respectively, will depend upon the nature of the activated derivative. However, in general the reaction between the compounds (11) and (VI), or (V) and (VII), may be carried out in a non-aqueous medium such as, for example, dimethylformamide, tetrahydrofuran, acetonitrile or a halohydrocarbon such as dichloromethane at a temperature within the range -250C to +1500C. The reaction may optionally be carried out in the presence of a base such as triethylamine or pyridine and the base may also be used as the solvent for reaction.
Where acid chlorides are used, the reaction may be carried out using the Schotten-Baumann technique in the presence of a suitable base, for example, aqueous sodium hydroxide, conveniently at a temperature between 0 C and 100"C, for example, room temperature.
According to another general process (3A), the compounds of general formula (I) may be prepared by treating a compound of formula (Xa)
(where Y represents a bromine or iodine atom or the group -OSO2CF3) with a compound of formula (XIa)
or an ester, an anhydride or a salt (e.g. lithium) thereof.
Alternatively, according to the general process (3B), the compounds of general formula (I) may be prepared by treating a compound of formula (Xb)
or an ester, an anhydride or a salt (e.g. lithium) thereof; with a compound of formula (XIb)
where Y represents a bromine or iodine atom or the group -OSO2CF3.
Both reactions may be effected in the presence of a transition metal catalyst such as (Ph3P)yd (where Ph represents phenyl) in a suitable solvent such as an ether (e.g.
1,2-dimethoxyethane or tetrahydrofuran) in the presence or absence of water, or an aromatic hydrocarbon (e.g. benzene). The reaction is preferably carried out in the presence of a base such as an alkali or alkaline earth metal carbonate (e.g. sodium carbonate) at a suitable temperature up to reflux.
According to another general process (4), the compounds of general formula (I) may be prepared by reducing a compound of formula (XII)
(where W represents a group convertible to the group -(CH2)pNRR under reducing conditions).
Examples of the type of group W which may be converted into the group -(CH2)pNRR are: -(CH2)p lCN, -(CH2)p-1CHO, and when p is 3, -C=CCN, -CH=CHCN, -CH=CHCHO, -CH=CHCH2NRIlRl2 or -C-CCH2NR"RI2. When W contains an aldehyde as defined above, the conversion is carried out in the presence of an appropriate amine of formula NHR"R'2. When W contains a nitrile as defined above, the conversion may be carried out in the presence of an amine of formula NHR'1R'2, with the proviso that R'l and Rl2 do not both represent a hydrogen atom, in order to obtain a secondary or tertiary amine of general formula (I).
The reaction may be effected using an alkali or alkaline earth metal borohydride, e.g.
sodium borohydride, or hydrogen and a metal catalyst such as palladium or platinum or oxides thereof. The reaction may be carried out at a temperature between 0 C and 100 C, conveniently at room temperature, and preferably in a solvent.
Suitable solvents for chemical reduction include ethers e.g. tetrahydrofuran, or alcohols e.g. ethanol. Suitable solvents for catalytic reduction include alcohols e.g.
ethanol, ethers e.g. dioxan, amides e.g. dimethylformamide or a mixture of solvents e.g.
ethanol/dimethylformami de.
According to another general process (5), the compounds of general formula (I) in which X represents either of the groups -NHCH2- or -CH2NH- may be prepared by reduction of the corresponding compounds of general formula (I) in which X represents the groups -NHCO- or -CONH-, respectively, except that the reaction cannot be used to prepare compounds in which R2 and/or R represents another group reducible under the reaction conditions, for example, CONR6R7, CONR6(CH2)mCO2R7, SO2R6, CO2H, COR6, SOR6, CN, NO2 or -(CH2)nOC(O)C1-4alkyl.
The reduction may be effected using a suitable metal hydride such as lithium aluminium hydride in a solvent e.g. an ether (such as tetrahydrofuran) at a temperature in the range of-10 C to +100 C.
According to another general process (6A), the compounds of general formula (I) in which X represents the group -NHCH2- may be prepared by reacting an aniline of formula (V) with an aldehyde of formula (XXIII)
under reducing conditions.
Alternatively, according to general process (6B), the compounds of general formula (I) in which X represents the group -CEI2NH- may be prepared by reacting an aniline of formula (11) with an aldehyde of formula (XXIV)
under reducing conditions.
Both reactions may conveniently take place in the presence of a solvent such as an alcohol e.g. methanol or ethanol using for example a hydride reducing agent such as an alkali or alkaline earth metal borohydride (e.g. sodium borohydride or sodium cyanoborohydride). The reactions may be carried out at a temperature in the range from 0 to 600C, conveniently at room temperature.
Compounds of general formula (I) in which R2, R3, R4 and R5 have a particular meaning may be converted into another compound of the invention by standard methods of interconversion.
For instance, when R2 and/or R; represents a hydroxy or alkoxy group and/or when R4 and/or R5 represents hydroxy or alkoxy these groups may be interchanged by standard methods of O-alkylation or O-dealkylation. Thus, for example, a compound in which R4 represents hydroxy may be prepared by treating a corresponding compound in which R4 represents methoxy with a reagent system capable of removing the methyl group e.g. a mercaptide such as sodium ethylmercaptide in a solvent such as dimethylformamide, lithium iodide in collidine, boron tribromide in a halohydrocarbon solvent e.g. methylene chloride or molten pyridine hydrochloride.
When R2 represents a hydroxymethyl group this may be converted by oxidation into a corresponding compound of general formula (I) in which R2 represents a group COR6 (where R6 is a hydrogen atom) or CO2H. Thus, for example, oxidation may be effected using a suitable oxidising agent such as a manganese oxidising agent (e.g. manganese dioxide) in a solvent such as an ether (e.g. 1,4-dioxan) at a suitable temperature up to reflux, a chromium oxidising agent (e.g. Jones reagent) or pyridinium dichromate in a suitable solvent such as a halohydrocarbon (e.g. methylene chloride). When R2 represents an aldehyde group this may be converted by oxidation into a corresponding compound of general formula (I) in which R2 represents a group CO2H.
Thus, for example, oxidation may be effected using a suitable oxidising agent such as a source of silver (I) (e.g. silver nitrate) in aqueous alkali optionally in the presence of a cosolvent such as an alcohol (e.g. methanol).
Intermediates of formula (I1) may be prepared by reduction of a compound of formula (XIII)
(where W is as defined in formula (XII)) under the reducing conditions described for process (4).
Compounds of formula (XIII) may be prepared by reduction of the corresponding nitro compounds of formula (XIV)
Suitable reducing conditions include, for example, catalytic hydrogenation using a metal catalyst such as palladium oxide on a support such as charcoal, optionally in a solvent such as an alcohol (e.g. ethanol) or an ether (e.g. tetrahydrofuran). Under such conditions, the group W may also be reduced and hence the intermediates of formula (II) may be prepared directly from the compounds of formula (XIV) without prior isolation of the compounds of formula (XIII).
The nitro compounds of formula (XIV) may be prepared from the corresponding halo compounds of formula (XV)
(where Hal is bromine or iodine) using standard methodology.
Intermediates of formula (IV) may be prepared by the following reaction sequence:
Step (a) is carried out using suitable halogenating conditions, for example, when Hal represents iodine the iodine atom may be introduced using iodine monochloride in a solvent such as methylene chloride; step (b) is carried out under standard brominating conditions such as using phosphorous tribromide in a halohydrocarbon solvent or using carbon tetrabromide in the presence of triphenylphosphine; and step (c) is carried out using an amine R1 1R12NH in a suitable solvent such as ethanol, preferably in the presence of a base; with the proviso that either R4 or R5 is a directing group (i.e. fluorine, chlorine, hydroxy, Cl 6alkoxy or C,4alkyl) in a position either ortho or para to the group (CH2)nOH.
Intermediates of formula (V) may be prepared by reaction of a compound of formula (XIa) or (XIb) with a compound of formula (XVIa) or (XVIb), respectively,
according to the method of general process (3).
Intermediates of formula (II) or (V) may also be prepared from the corresponding carboxylic acid of formula (IX) or (VIII), respectively, using conventional procedures (e.g. by Curtius rearrangement).
Intermediates of formula (Xa) and (Xb), in which X is -CONH-, may be prepared by reaction of a compound of formula (H) with a compound of formula (XVIIa) or (XVIIb), respectively,
according to the method of general process (2).
Intermediates of formulae (Xa) and (Xb), in which X is -NHCO-, may be prepared by reaction of a compound of formula (IV) with a compound of formula (XVIa) or (XVIb), respectively, according to the method of general process (1).
Intermediates of formula (XII), in which X is -CONH-, may be prepared by reaction of a compound of formula (XIII) with a compound of either formula (III) or (VI) according to the method of general process (1) or (2), respectively.
Alternatively, intermediates of formula (XII), in which W is -CH=CHCHO, -CH=CHCN, -CH=CHCH2NR"R'2 or -C=CCH2NRl'R'2, may be prepared from a compound of formula (XVIII)
(wherein Hal is the only bromine or iodine atom in the molecule) by reaction with an alkene: EtC=CHCHO, RC=CHCEI2NR"R'2 or RC=CHCN; or an alkyne: HC=CCH2NRR.
The reaction may be effected in the presence of a palladium reagent and preferably in the presence of a base The palladium reagent may be, for example, a palladium salt derived from an organic acid (e.g. an acetate) or derived from an inorganic acid (e.g. a chloride or bromide), a palladium complex such as a triarylphosphine palladium complex (e.g. triphenylphosphine or tri(2-methylphenyl)phosphine palladium complex), or a finely divided palladium metal such as palladium on charcoal. The triarylphosphine palladium complex may be generated in situ by reacting a palladium salt (e.g. palladium acetate) with the appropriate triarylphosphine.
Suitable bases include tertiary amines (e.g. triethylamine or tri-n-butylamine) or alkali metal (e.g. sodium or potassium) carbonates, bicarbonates and acetates.
The reaction may be effected in the presence or absence of a solvent. Suitable solvents include nitriles (e.g. acetonitrile), amides (e.g. dimethylformamide, N-methylpyrrolidinone) and water. The reaction may conveniently be carried out at a temperature between room temperature and 200 C, preferably between 50 C and 1600C. Compounds of formula (XVIII) may be prepared by the reaction of a compound of formula (V) or (VI) with a compound of formula (XIX) or (XX), respectively,
according to the method of general process (2).
Alternatively, intermediates of formula (XII) in which W is -(CH2)p-1CN or -(CH2)p-1CHO may be prepared by the reaction of a compound of formula (III) or (V) with a compound of formula (XXI) or (XXII), respectively,
(wherein W' represents -(CEI2)p,CN or -(CH2)p-1CHO), according to the method of general process (1).
Intermediates of formulae (XM) and (XXII) in which W' contains a nitrile group may be prepared from the corresponding halo (e.g. bromo) compound using standard methodology.
It will be appreciated that, where necessary, a halogen substituent may be converted into a carboxyl group using standard methodology thus, for example, compounds of formula (VIII) or (IX) may be prepared from an intermediate of formula (III) or (IV), respectively, by lithiation using, for example, n-butyl lithium followed by quenching with carbon dioxide.
The boronic acid intermediates of formulae (Xb), (XIa), (XVIb) and (XVIIb) or their esters, anhydrides or salts may be used in situ under the conditions described above for general process (3).
The aldehydes of formula (XXIII) or (XXIV) may be prepared from an intermediate of formula (IV) or (III), respectively, by lithiation using, for example, n-butyl lithium followed by formylation using, for example, dimethylformamide.
Intermediates of formulae (III), (XIa), (XIb), (XV), (XVIa), (XVIb), (XVIIa), (XVIIb), (XIX) and (XX) are either known compounds or may be prepared by standard methodology or methods analogous to those described herein.
Physiologically acceptable acid addition salts of the compounds of general formula (I) may be prepared by treating the corresponding free base with a suitable acid using conventional methods. Thus, for example, a generally convenient method of forming the acid addition salts is to mix appropriate quantities of the free base and the acid in an appropriate solvent e.g. an alcohol such as ethanol or an ester such as ethyl acetate.
Inorganic basic salts of compounds of general formula (I) may be prepared by treating the corresponding acid of general formula (I) (i.e. a compound of general formula (I) in which R2 and/or R3 represents the group CO2H) with a suitable base using conventional methods.
The invention is illustrated but not limited by the following examples in which temperatures are in OC. Thin layer chromatography (T.l.c.) was carried out on silica plates. Dried' refers to drying using sodium sulphate or magnesium sulphate unless otherwise stated. Flash column chromatography (FCC) was carried out on silica gel (Merck 9385) unless otherwise stated, Short path column chromatography (SPC) was carried out on silica gel (Merck 7747) unless otherwise stated.
The following solvent systems were used:- System A - dichloromethane:ethanol:0.88 ammonia; System B - dichloromethane:ethanol; System C - hexane:diethyl ether; System D - dichloromethane:hexane; System E - ethyl acetate:ethanol:triethylamine; System F dichloromethane:methanol:0.88 ammonia; System G - chloroform:methanol:0.88 ammonia.
The following abbreviations are used:- ether - diethyl ether; DMF dimethylformamide; THF - tetrahydrofuran; AIBN - azobisisobutyronitrile; DME 1 ,2-dimethoxyethane.
Intermediate 1 (a) 3-[3-(Dimethylamino)-1-propynyl]-4-methoxybenzoic acid A mixture of 3-iodo4-methoxybenzoic acid (400mg), N,N-dimethyl-2- propynamine (0.22ml), copper (I) iodide (14mg), dichlorobis(triphenylphosphine)palladium (II) (31mg), triethylamine (3ml) and DMF (2ml) was stirred at reflux under nitrogen for 5h.
When cool, the mixture was evaporated and the residue purified by FCC using gradient elution with System A (134:60:6 to 50:45:5) to afford a solid which crystallised from ethanol to give the title compound (85mg) as fine cream crystals, m.p. 167-169.5 .
Similarly prepared was: (b) 4-Methoxy-3-[3-(methylamino)-1-propynyl]benzoic acid (1 .97g), T.l.c. (System A 10:8:1) Rf0.25 From 3-iodo4-methoxybenzoic acid (3.0g) and N-methyl-2-propynamine (2.24g) using acetonitrile as reaction solvent. The title compound was obtained without crystallisation.
Intermediate 2 3-[3-(Dimethylamino)propyl]-4-methoxybenzoic acid A solution of Intermediate l(a) (2.81g) in DMF (40ml) and ethanol (20ml) was added to a pre-reduced suspension of 10% palladium oxide- on-carbon (1.5g) in ethanol (20ml) and hydrogenated at room temperature and pressure until uptake ceased. The catalyst was filtered off, the filtrate evaporated, and the residue crystallised from acetonitrile (45ml) to give the title compound (1.90g) as fine white crystals, m.p.l35-137.50.
Intermediate 3 5-Iodo-2-methoxybenzenepropanol A solution of iodine monochloride (17.0g) in methylene chloride (55ml) was added dropwise, under nitrogen, over a period of 0.5h to a stirred, ice-cooled solution of 2-methoxybenzenepropanol (10.0g) in methylene chloride (50ml). The dark solution was stirred, with ice cooling for 1.25h and then washed with 20% aqueous sodium thiosulphate solution. The pale yellow organic solution was then dried and concentrated in vacuo to give the title compound (16.38g) as a pale pink solid, m.p. 68-700.
Intermediate 4 2-(3 -Bromopropvl)-4-iodo-1-methoxvbenzene A solution of triphenylphosphine (18.5g) in methylene chloride (120ml) was added dropwise under nitrogen to a stirred, cooled solution of Intermediate 3 (13.3g) and carbon tetrabromide (19.2g) in methylene chloride (200ml). The orange solution was stirred, with external cooling, for 2h and then concentrated in vacuo. Purification by FCC of the residual solid (Merck 7734) eluting with hexane afforded the title compound (15.35g) as a colourless oil.
T.l.c. (hexane) Rf0.39.
Intermediate 5 5-Iodo-2-methoxv-N.N-dimethvlbenzenepropanamine hvdrochloride A solution of Intermediate 4 (500mg) in a mixture of 33% ethanolic dimethylamine (lOml) and absolute ethanol (2ml) was stirred at reflux under nitrogen for 2h, allowed to cool, and then concentrated in vacuo. Purification by FCC of the residual white solid eluting with System A (200:10:1) afforded a colourless oil which contained the free base of the title compound (272mg) as a white solid. This material was dissolved in refluxing absolute ethanol (Iml) and ethereal hydrogen chloride (0.5ml) was added. The stirred solution was diluted with dry ether (loll) and the resultant solid filtered off, washed with dry ether and dried in vacuo at 600 for 20h to give the title compound (195mg) as a white solid, m.p. 143-144 .
Intermediate 6 [4-[Bis(phenylmethyl)amino]phenyl]boronic acid n-Butyllithium (1.60M in hexane, 98ml) was added dropwise under nitrogen to a stirred solution of N-(4-bromophenyl)-N-(phenylmethyl)benzenemethanamine (50.0g) in dry THF (500ml) at -67 to -65 over 30 min. After lh, triisopropylborate (57ml) was added dropwise over 20min and the mixture stirred at 230 for 16h. Water (80ml) was added, the mixture was evaporated, and then co-evaporated with ethanol (2x100ml). The residue was treated with dichloromethane (200ml) and the slurry purified by FCC using gradient elution with a gradient of System B (1:0) to (97:3) to afford the title compound (5.6g) as fine cream crystals.
T.l.c. System B (50:1)Rf0.16.
Intermediate 7 3 '-Amino F 1.1 '-biphenyll-4-carboxamide A solution of 4-bromobenzamide (2.15g) and 3-aminophenylboronic acid hemisulphate (2.00g) in DME (100ml) was treated with a solution of sodium carbonate (1.71g) in water (SOml), followed by tetrakis(triphenylphosphine)palladium (0) (496mg) and then stirred at reflux under nitrogen for 3h. When cool, the mixture was evaporated, treated with aqueous 2M sodium carbonate (200ml) and extracted with ethyl acetate (4x120ml).
The combined, dried organic extracts were evaporated and the residue crystallised from ethanol to give the title compound (1.03g) as fine cream crystals, m.p. 206-2080.
Similarly prepared was: Intermediate 8 (a) 4'-iBis(Dhenvimethvl)aminol T1.1 '-biDhenvll-3-carboxamide (4.00g), as fine white needles, T.l.c. (ether) Rf0.11.
From 3-bromobenzamide (4.63g) and Intermediate 6 (7.34g) with recrystallisation from ethyl acetate.
(b) 4'-[Bis(phenylmethyl)amino]-N,N-dimethyl[1,1'-biphenyl]-4- suiphonamide (0.74 g) as fine white needles, m.p. 181.5-185.5 .
From Intermediate 6 (5.00g) and 4-bromo-N,N-dimethyl-benzenesulphonamide (4.16g) except that 1M sodium carbonate (200ml) was used in the work-up procedure.
(c) $4'-[Bis(phenylmethyl)amino][1,1'-biphenyl]-4-carboxamide (6.44g) as fine white needles, m.p. 199-200.5 .
From Intermediate 1 (8.00g) and 4-bromobenzamide (5.04g) except that the residue was suspended in 1M sodium carbonate (lSOml), the solid filtered off, dried and treated with refluxing acetonitrile (600ml). The mixture was then filtered, the filtrate heated to reflux and the precipitate, which resulted upon cooling, filtered off The mother liquors were evaporated and the residue crystallised from acetonitrile to give a further crop of the title compound (1.78g).
(d) 4'-[Bis(phenylmethyl)amino]-N,N-dimethyl[1,1'-biphenyl]-4- carboxamide (3.48g) as white crystals, m.p. 133-135 (softens 860).
From Intermediate 6 (5.00g) and 4-bromo-N N-dimethylbenzamide (3.72g) except that the product was crystallised from ethanol:ethyl acetate (1:2). Further recrystallisation of the mother liquors gave the title compound (1.82g) as white crystals.
(e) 4'-[Bis(phenylmethyl)amino]-3-hydroxy[1,1'-biphenyl]-4-carboxylic acid (2.23g) as a crystalline solid, m.p. 224-228 (dec).
From 2-hydroxy-4-iodobenzoic acid (2.11g) and Intermediate 6 (2.54g) with a reaction time of 30h after which the mixture was cooled and filtered, washing well with water.
The filtrate was acidified to pH6 with 2N sulphuric acid and extracted with ethyl acetate (3x100ml). The combined extracts were dried and evaporated to give a yellow solid (3.58g). FCC using dichloromethane:acetic acid (100:1) as eluent, gave the title compound.
(f) 1-[4'-[bis(phenylmethyl)amino][1,1'-biphenyl]-4-yl]ethanone (2.01g) as fine cream-coloured crystals, m.p. 140-1430.
From Intermediate 6 (4.00g) and 1-(4-bromophenyl)ethanone (2.51g). The residue was crystallised from ethyl acetate to give a crop of impure product (3.76g) and the mother liquors were concentrated to give a second crop (0.66g). The first and second crops were combined and purified by FCC eluting with System C (9:17:3) to afford the title compound.
(g) 1-[4'-[Bis(phenylmethyl)amino][1,1'-biphenyl]-2-yl]ethanone (1.07g) as a yellow gum. T.l.c. (dichloromethane) Rf0.51.
From Intermediate 6 (0.96g) and 2-bromoacetophenone (0.72g) with purification by FCC eluting with System D (3:7) followed by (1:1).
(h) N-(4'-Methoxy 1 '-biphenvil -4-yl)-N-(phenylmethyl)-benzenemethanamine (1.58g) as a colourless crystalline solid, m.p. 100-1020.
From Intermediate 6 (1.903g) and 4-iodo-1-methoxybenzene (1.404g). Except that after 4.5h the reaction mixture was cooled, poured into water (200ml), and extracted with ether (500ml and 100ml). The combined extracts were dried and evaporated to give a brown oil, which was purified by FCC, using ethyl acetate:hexane (1:50 followed by 1:20) as eluents to give the title compound.
(i) 4'-(Aminocarbonyl)[1,1'-biphenyl]-4-carboxylic acid (441mg), T.l.c. (ethyl acetate) Rf 0.27.
From 4-bromobenzamide (777mg) and 4-boronobenzoic acid (677mg). When cool, the reaction mixture was evaporated, and treated with aqueous 2M-hydrochloric acid (60ml).
The solid was filtered off, dried in vacuo over phosphorus pentoxide, and then crystallised from acetic acid to give the title compound.
Intermediate 9 4'-Amiono-&alpha;-methyl[1'1-biphenyl]-2-methanol A solution of Intermediate 8(g) (5.60g) in 2-methoxyethanol (200ml) was added to a suspension of wet 10% palladium on carbon (2.5g) in 2-methoxyethanol (50ml) and the reaction mixture was hydrogenated at room temperature and pressure for 16h. The catalyst was filtered off and the filtrate was adsorbed onto silica gel. The residue was purified by FCC eluting with System C (3:1) followed by (1:3) to give the title compound (2.55g) as an off-white solid, m.p. 108- 1120.
Similarly prepared was: Intermediate 10 4'-Amino-3-hydroxy[1,1'-biphenyl]-4-carboxylic acid (981mg), m.p. 212-214 dec.
From Intermediate 8(e) (2.16g) using 2-methoxyethanol as solvent. The crude product (1.23g) was crystallised from aqueous methanol to give the title compound.
Concentration ofthe mother liquors gave a second crop (133mg).
Intermediate 11 4'-Amino-N.N-dimethvlrl .1 '-biphenl 4-carboxamide A solution of Intermediate 8(d) (5.21g) in THF (100ml) was added to a suspension of 10% palladium on carbon (2.40g) in ethanol (30ml) and the mixture hydrogenated at room temperature and pressure for 20h. The catalyst was filtered off and the solution evaporated to give cream crystals. Recrystallisation of the crystals from ethyl acetate-tetrahydrofuran (1:1) gave the title compound (1.58g) as white crystals, m.p.
184.0-186.5 . Recrystallisation of the mother liquors gave a further crop of the title compound (274mg) as beige crystals.
Intermediate 12 4'-Amino[1,1'-biphenyl]-4-carboxamide A solution of Intermediate 3 (7.75g) in dry THF (200ml) was added to a mixture of pre-reduced 10% palladium oxide-on-carbon (3.00g) and the stirred suspension hydrogenated at room temperature and pressure until uptake ceased. The catalyst was filtered off, the filtrate evaporated, and a solution of the residue in DMF (150ml) was added to a mixture of pre-reduced 10% palladium oxide-on-carbon (2.00g) in ethanol (25ml). The stirred suspension was hydrogenated at room temperature and pressure until uptake ceased. The catalyst was filtered off and the filtered pad washed with hot ethanol.
The filtrate and washings were evaporated to give a solid (4.00g). A portion of the solid (500mg) was recrystallised from acetonitrile to give the pure title compound (56mg) as fine light grey crystals, m.p. 281-2840.
Intermediate 13 4'-Amino-&alpha;-methyl[1,1'-biphenyl]-4-methanol A solution of Intermediate 8(f) (1.80g) in dry THF (22ml) was added to a suspension of 10% palladium oxide-on-carbon (0.9g) in dry iliP (15ml) and the stirred mixture hydrogenated at room temperature and pressure. The catalyst was filtered off and the filtrate evaporated and purified by FCC. Elution with System C (3:10:1) afforded the title compound (645mg) as fine white crystals, m.p. 111-1150.
Similarly prepared were: Intermediate 14 (a) 4'-Ethyl[1,1'-biphenyl]-4-amine (84mg), m.p. 67-770.
From a more extensive hydrogenation with 10% palladium oxide on carbon of Intermediate 8(f) (1.80g).
(b) 4'-Amino-3-hydroxy[1,1'-biphenyl]-4-carboxylic acid (981mg) as light brown needles, m.p. 212-214 dec.
From Intermediate 8(e) (2.16g) with purification by crystallisation from aqueous methanol. Concentration ofthe mother liquors gave a second crop (133mg).
Intermediate 15 4'-Amino-N,N-dimethyl[1,1'-biphenyl]-4-sulphonamide A solution of Intermediate 8(b) (4.28g) in DMF (lOOml) was added to pre-reduced 10% palladium oxide-on-carbon (2.00g) in ethanol (30ml) and the stirred suspension was hydrogenated at room temperature and pressure until uptake ceased. The catalyst was filtered off, the filtrate evaporated, and the residue purified by SPC. Elution with dichloromethane afforded a solid which crystallised from ethanol to give the title compound (916mg) as fine white needles, m.p. 178.5- 180 . The mother liquors were concentrated to give a further crop of the title compound (176mg). Further elution of the column gave another crop of the title compound (775mg).
Similarly prepared were: Intermediate 16 (a) 4'-AminoT1.1'-biDhenvll-3-carboxamide (1.28g), m.p. 187.51900.
From Intermediate 8(a) (3.99g), with purification by crystallisation from ethanol. The mother liquors were evaporated to give a second crop of the title compound (551mg).
T.l.c. (ethyl acetate:hexane, 1:1) Rf 0.04.
(b) 4-Methoxy-3-[3-(methylamino)propyl]benzoic acid hydrochloride (2.1 0 m.p.
195-1980C.
From Intermediate 1(b). The catalyst was filtered off and the solvent was then evaporated to give the title compound.
Intermediate 17 [4-(Methylsulphinyl)phenyl]boronic acid A solution of [4-(methylthio)phenyl]boronic acid (1.008g) in acetonitrile (60ml) and water (6ml) was cooled with a dry ice- acetone bath until it just began to freeze. A solution of ceric ammonium nitrate (6.72g) in water (10ml) was added with swirling. The resulting solution was left to warm to room temperature. The mixture was then basified to pH5 by addition of 8% aqueous sodium bicarbonate (16ml) and evaporated to dryness by re-evaporation with absolute ethanol. The dried residue was purified by SPC (Merck 7729) using ethyl acetate:ethanol (9:1 followed by 4:1 and 7:3) as eluent, to give impure product (2.6g) as a colourless solid.The solid was further punted by FCC eluting with System B (9:1) to give the title compound (1.004g) as a colourless gum.
T.l.c. System B (9:1) Rf 0.35.
The gum was dissolved in warm water and the solution evaporated to give a colourless crystalline solid (847mg). Recrystallisation from water (15ml) gave a further crop of the title compound (697mg) as almost colourless needles.
Analysis Found: C,45.6; H,4.85; S,17.55.
C7EIgB03S requires: C,45.7; H,4.95; S,17.4% Intermediate 18 5-Bromo-2-methoxy-N,N-dimethylbenzeneethanamine Dimethylamine (30% w/v in industrial methylated spirits, 20ml) was added to a stirred solution of 4-bromo-2-(2-bromoethyl)-1-methoxybenzene (2.95g) in ethanol (10ml) and THF (5ml) and heated at reflux for 1.5h. The cooled solution was evaporated, treated with aqueous saturated sodium bicarbonate (50ml), and extracted with ethyl acetate (5x50ml). The combined, dried organic extracts were evaporated, and the residue purified by FCC using gradient elution with System A (967:30:3 to 945:50:5) to afford the title compound (1.90g) as a pale yellow oil.
T.l.c. System A (945:50:5) Rf 0.21.
Intermediate 19 3-[2-(Dimethylamino)ethyl]-4-methoxybenzoic acid hydrochloride Tert-butyllithium (1.8M in pentane, 5.75ml) was added dropwise under nitrogen at -780 to a stirred solution of Intermediate 18 (1.485g) in dry TG (15ml) and stirring was continued for 15min at -780 Carbon dioxide was passed through the solution for 15min and then the reaction was stirred at 230 for lh with carbon dioxide passing through it.
The mixture was evaporated and the residue purified by FCC using gradient elution with System A (89:10:1 to 50:45:5) to afford a white solid (1.315g). A portion of this (220mg) was recrystallised from ethanol (2.5ml) to give the title compound (51mg) as fine white crystals.
T.l.c. System A (50:45:5) Rf0.1.
Intermediate 20 N-(4-Bromophenyl)-3-[3-(dimethylamino)propyl]-4-methoxybenzamide (i) 3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl chloride. hydrochloride Thionyl chloride (3.5ml, 5.7g) and dry DMF (2 drops) was added to Intermediate 2 (1.5g) and the mixture heated on a steam bath for 5 min. The excess thionyl chloride was evaporated under reduced pressure whilst heating and the solid residue which formed re-evaporated with dry toluene (15ml x 2) then dried in vacuo to give the title compound as a buff powder (1.88g).
(ii) N-(4Bromophenvi)-3-3 -(dimethyl amino)propvll methoxybenzamide The product of step (i) (5.84g) was treated with 4-bromobenzamine (3.4g) and dry pyridine (20ml) and heated at reflux under nitrogen for 1.5h. When cool, water (20ml) was added, followed by solid sodium carbonate (Ig) and the solution evaporated in vacuo affording a grey-white residue which was washed with water, filtered, air-dried, and recrystallised from ethyl acetate to give the title compound as a cream solid (3.93g) m.p.
145.5-146 C.
Evaporation of the filtrate yielded further solid, which was re- crystallised from ethyl acetate to give a second crop of crystals (1.79g) m.p. 145.5-146 C Intermediate 21 N-(4-Bromophenyl)-3-[3-(dimethylamino)propyl]-4-hydroxybenzamide Intermediate 20 (1.32g) was added to a solution of boron tribromide in dichloromethane (1M; 112.8ml under nitrogen and the mixture stirred for 5h before adding methanol (20ml). The solvent was evaporated in vacuo and the residue purified by FCC eluting with System A (189:10: 1) to give the title compound (700mg) as a white powder.
Analysis Found: C,57.2; H,5.7; N,7.2.
C18H21BrN2O2 requires C,57.3; H,5.6; N,7.4%.
Intermediate 22 4'-Amino-3 -hydroxy [1.1 '-biphenyllA-methanol A stirred suspension of lithium aluminium hydride (500mg) in dry, redistilled lF (50ml) under nitrogen was treated with Intermediate 10 (500mg). The resulting green suspension was stirred at room temperature for 48h, quenched by careful addition of water, and diluted with saturated aqueous ammonium chloride (300ml), and extracted with ether (5 x 300ml). The combined extracts were dried and evaporated to give a light yellow brown solid (315mg). crystallisation from ethyl acetate-hexane gave the title compound (214mg) as light brown needles, T.l.c. ethyl acetate Rf 0.50.
Intermediate 23 [4-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]phenyl]boronic acid bimolecular anhvdride n-Butyl lithium (1.6M; 9.7ml) was added, over 8 min, under nitrogen to a stirred, cooled (-70) solution of 1-bromo-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]benzene (4g) in dry iliF (40ml). After a further 25 min, the resulting solution was added over 10 min to a stirred cooled (-66 ) solution of tri-isopropyl borate (lOml) in iliF (40ml) and the mixture stirred at room temperature for 2h. Water (lOml) and, after a further 5 min, pH 6.5 phosphate buffer (loom) and ether (50ml) were added and the mixture stirred vigorously for 10 min. The aqueous layer was extracted with ether (2x70ml) and the combined organic solutions dried and evaporated in vacuo to leave a white solid.
Crystallisation from ether gave the title compound (2.02g) as a white solid m.p. 193-70.
T.l.c. (dichloromethane:methanol, 96:4) Rf 0.56 Intermediate 24 N-[[4'-Nitro[1,1'-biphenyl]-4-yl)carbonyl]glycine ethyl ester To 4'-nitro[l,l-biphenyl]-4-carboxylic acid (3.65g) was added thionyl chloride (lOml) and DMF (0.2ml) and the mixture heated on a steam bath. The excess thionyl chloride was evaporated in vacuo and the residue re-evaporated with toluene (20ml) then ether (20ml x 2). The solid residue was suspended in pyridine (20ml) and glycine ethyl ester hydrochloride (2.30g) added and the mixture heated on a steam bath until complete solution had occurred. The solution was stood at room temperature for 45min then poured into water (300ml) and then acidified with 5N HCI.The mixture was extracted with ethyl acetate (150ml x 4) and the combined extracts dried and evaporated in vacuo to give a red residue which was suspended in cold ether and filtered to give a solid which was washed with ether and dried to give the title compound (4.606g) m.p. 145-1480.
Intermediate 25 N-[(4'-Amino[1,1'-biphenyl]-4-yl)carbonyl]glycine ethyl ester maleate (1:1) To a hot suspension of Intermediate 24 (1.49g) in ethanol (70ml) was added Raney Nickel (lg) and hydrazine hydrate (1.2ml) in 0.2ml portions dropwise during 20min with stirring. The mixture was heated on a steam bath and after the effervescence subsided, was heated for a further 20min. The suspension was filtered in a stream of nitrogen and the resulting suspension was evaporated to dryness and the residue extracted with hot ethyl acetate (loom) and filtered, and the filtrate evaporated to dryness.
The residue was suspended in cold ether, filtered, and the residue dried to give the free base of the title compound (0.963g) m.p. 174-1790. To a solution of the free base (O.lg) in ethyl acetate was added a solution of maleic acid (0.04g) in ethyl acetate The suspension was filtered, the residue washed with ethyl acetate and dried to give the title compound (0.108g) m.p.
149-151 .
Intermediate 26 (E)-3 -(2-Metho::v-3-nitrophenyl)-2-propenenitrile mixture with (Z) (1:1) A solution of 2-iodo-1-methoxy4-nitrobenzene (500g), acrylonitrile (0.14ml), triethylamine (0.62ml) and acetonitrile (1.2ml), was treated with palladium acetate (28mg) and heated at 1100 for 16h. When cool the mixture was poured into aqueous saturated sodium bicarbonate (30ml), extracted into ethyl acetate (3x30ml), and the combined, dried organic extracts were evaporated and purified by SPC and elution with System C (4:1 to 7:3) afforded the title compound (128mg) as white crystals.
T.l.c. System C (2:1) RfO.ll Intermediate 27 5 -Amino-2-methoxv-N N-dimethv!benzenepropanamine A solution of Intermediate 26 (4.33g) in dry THF (80ml) and ethanolic dimethylamine (33% w/v, 80ml) was added to a suspension of pre-reduced 10% palladium oxide on carbon (2.00g) in ethanol (30ml) and the stirred mixture hyrogenated at room temperature and pressure for 5h. The catalyst was filtered off and the filtrate evaporated. A solution of the filtrate in ethanolic dimethylamine (100ml) was added to a suspension of pre-reduced 10% palladium oxide on carbon (2.00g) in ethanol (30ml) and the stirred mixture hydrogenated at room temperature and pressure for 16h. The catalyst was once again replenished as above and hydrogenation continued for 70h.The catalyst was filtered off and the filtrate was purified by SPC with gradient elution using System A (945:50:5 to 912:80:8) to afford the title compound (3.20g) as a light brown oil.
T.l.c. System A (89:10:1) Rf0.12.
Intermediate 28 (4-Formvl-2-methvlphenvl)boronic acid A stirred solution of 2,5-dibromotoluene (5.00g) in dry THF (200ml) under nitrogen at -780 was treated dropwise with n-butyllithium (11.8ml, 1.69M in hexane). After lh, DMF (1.6ml) was added and the mixture was allowed to warm to 00 and then recooled to -780 and treated with more n-butyllithium (11.8ml, 1.69M in hexane). After lh, triisopropylborate (7.0ml) was added and the cooling bath removed. After lh, 2N hydrochloric acid (80ml) was added and the ThF removed under vacuum. The residue was extracted with ether (3 x 1 OOml) and the combined extracts were dried and evaporated to give an oil.SPC (Merck 7729) using chloroform:ethanol (50:1) as eluent gave the product (2.21g) as an almost colourless oil. Addition of acetone (50ml) and water (50mi) and evaporation to dryness gave the title compound (1.31 g) as a colourless solid.
T.l.c. (chloroform:ethanol 50:1) Rf0.25.
Intermediate 29 C-MethoxvF1.1 '-biphenvll-4-amine, hydrochloride A stirred mixture of Intermediate 8(h) (1.50g), 10% palladium oxide on carbon (400mg of 50%w/w wet material), and 2N hydrochloric acid (3ml) in ethanol (40ml) was hydrogenated at room temperature and pressure. After 3h the reaction mixture was filtered and the filtrate was evaporated to dryness to give an almost colourless solid.
Crystallisation from absolute ethanol gave the title compound (543mg) as almost colourless plates, m.p. 232-2340 dec.
Intermediate 30 [4-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amino]phenyl]boronic acid A stirred solution of Intermediate 20 (3g) in dry ThF (125ml), under nitrogen at -780C was treated dropwise with n- butyllithium (10.lml of a 1.52M solution in hexane). After lh, triisopropylborate (4.4ml) was added dropwise at -780C, and the reaction was allowed to stir for 30min. The cooling bath was then removed, and the reaction was stirred under nitrogen at 280C for 17h. Hydrochloric acid (2N; 4ml) and water (50ml) were added, the reaction mixture evaporated to dryness, and purified by FCC eluting with System A (75:23:2) to give the title compound as a cream foam (1.14g).
T.l.c. System A (60:40:4) Rf 0.26 Intermediate 31 4-(T3romomethyl)-2-chloro 1 -iedobenzene A mixture of 2-chloro-1-iodo-4-methylbenzene (lg), N-bromosuccinimide (0.78g), AIBN (25mg), and carbon tetrachloride (15ml), was heated at reflux using a 150W light bulb for 4h. When cool, the reaction mixture was evaporated in vacuo and the residue was purified by FCC eluting with hexane to give the title compound as a colourless oil (0.833g).
T.l.c. hexane:ethyl acetate (20:1) Rf 0.65.
Intermediate 32 3-chloro4-iodobenzene methanol A mixture of Intermediate 31 (2g), potassium acetate (0.93g) and ethanol (95%, 10ml) was heated at reflux for 12h. When cool, the reaction mixturen-as filtered and the filtrate was treated with potassium hydroxide (0.41g), and allowed to reflux under nitrogen for 16h. When cool, the reaction mixture was evaporated to dryness, and the resultant yellow solid was purified by FCC, eluting with hexane:ethyl acetate (8:1), to give the title compound as a colourless solid (0.97g) m.p. 80-820C.
Intermediate 33 4-Bromo-3-methvlbenzenemethanol Diborane in THF (1M; 220ml) was added dropwise to a solution of the 4-bromo-3-methylbenzoic acid (20.0g) in lF (100ml) at room temperature under nitrogen. The solution was stirred for 5h, treated cautiously with water (20ml) and aqueous sodium hydroxide (2N; 200ml) and extracted with ether (3x100ml). The dried extract was evaporated to give the title compound as a colourless oil (11.8g).
T.1.c. System C (1:1) Rf. 0.35.
Intermediate 34 1 -Bromo4-(methoxvmethvl)-2-methvlbenzene Sodium hydride (80% disp;60mg) was added in one portion to a solution of Intermediate 33 (300mg) and iodomethane (425mg) in DMF (2ml) at room temperature under nitrogen. The resulting mixture was stirred for 16h, treated with water (20ml) and extracted with ether (2x30ml). The ether extract was washed with water (25ml), dried and evaporated to give the title compound as a yellow oil (340mg).
T.l.c System C (9:1), Rf 0.6.
Intermediate 35 4'-[Bis(phenylmethyl)amino]-2-methyl[1,1'-biphenyl]-4-ol hydrochloride From a hot mixture of 4-bromo-3-methylphenol (2.0g) and Intermediate 6 (3.4g) according to the method of Intermediate 7. Purification of a portion of the product (1 00mg) was effected by dissolving the product in the minimum quantity of refluxing ethyl acetate and then treating it with ethereal hydrogen chloride to yield the title compound as a white solid (72mg) m.p 158-1620C (1400C-reddens).
Similarly prepared was : Intermediate 36 4'-[Bis(phenylmethyl)amino][1,1'-biphenyl]-4-carboxamide as fine white needles (6.44g) m.p. 199-2000C.
From 4-bromobenzamide (5.04g) and Intermediate 6 (8.00g) using refluxing acetonitrile instead of ethyl acetate in the purification step.
Intermediate 37 4'-Amino-2-methvl[1 1 '-biphenvilA-ol A solution of the free base of Intermediate 35 (2.75g) in ethanol (65ml) was added to a pre-hydrogenated mixture of 10% palladium on carbon (2.75g) in ethanol (lOml) and the stirred mixture hydrogenated at room temperature for 3h. The mixture was filtered, washing the filter pad with ethanol (1.25 litres) and the filtrate adsorbed onto silica gel (Merck 7734, 30ml). Purification by FCC eluting with hexane-ethyl acetate (2:1) gave the title compound as a cream-yellow solid (0.598g) which was crystallized from refluxing toluene (5ml) to give the pure title compound as an off-white solid (0.369g) m.p. 156-1570C.
Intermediate 38 4'-[Bis(phenylmethyl)amino][1,1'-biphenyl]-4-methanamine A cooled (ice-bath) suspension of lithium aluminium hydride (1.0g) in dry THF (125ml), was treated dropwise with a solution of Intermediate 36 (5.0g) in dry THF (250ml) and heated under nitrogen at reflux for 17h. The mixture was cooled (ice-bath) and treated dropwise with water (1.0ml) followed by 15% sodium hydroxide solution (1.0ml) then water (3.0ml). The resultant solution was evaporated to dryness and purified by SPC, eluting with System A (97:3:0.3). Increasing the polarity to 95:5:0.5 gave the title compound as a cream solid (5.76g) m.p. 122-1250C.
Intermediate 39 N-[4'-[Bis(phenylmethyl)amino][1,1'-biphenyl]methyl]acetamide Intermediate 38 (4.0g) in dry pyridine (60ml), was treated with acetyl chloride (1.14ml) at 0 C and stirred for 24h at room temperature under nitrogen. 8% sodium bicarbonate (120ml) was added and the mixture evaporated to dryness and the residue purified by FCC eluting with System A (96.5:3.5:0.35) to give the title compound as a yellow solid (4.29g) m.p. 133-1360C.
Intermediate 40 N-[4'-AminoE 1.1 '-biphenvl3methyl]acetamide A solution of Intermediate 39 (4.0g) and 2N HCI (1.9ml) in DMF (250ml), was added to a pre-hydrogenated mixture of 10% palladium on carbon (1.7g, dry catalyst) in DMF (300ml), and hydrogenated at room temperature and pressure for 5h. The catalyst was filtered off and washed well with DMF (3 litres) and hot ethanol (2 litres). 8% sodium bicarbonate solution was added (200ml) and the mixture was evaporated to dryness and purified by FCC eluting with System A (97:3:0.3) to give the title compound as a cream solid (1.29g) m.p.174-1750C.
Intermediate 41 (2-chloro4-methvlphenvl)boronic acid A stirred solution of 2-chloro-1-iodo4-methylbenzene (760mg) in dry THF (30ml) under nitrogen at -780C, was treated dropwise with n-butyl lithium, (2.04ml of a 1 62M solution in hexane). After 30min, trisopropylborate (0.84ml) was added dropwise at -780C, and the reaction mixture was stirred for 1 h. The cooling bath was then removed and the reaction mixture was stirred at 230C under nitrogen for 19h. Aqueous hydrochloric acid (2M, 2.4ml) was added and after stirring for 30min, the mixture was extracted with ether (3x20ml), discarding the aqueous phase. The combined organic extracts were washed with aqueous 2M sodium hydroxide (3x100ml), and the organic layer was discarded.The aqueous extracts were combined, acidified to pH1 with conc. hydrochloric acid and extracted with ether (3x200ml). The ethereal fractions were combined, dried and evaporated in vacuo to give the title compound as a grey solid (367mg) m.p. 187-1880C.
Intermediate 45 N-(4-Bromo-3-methylphenyl)-3-(3 -(dimethylamino)propyliA-methoxvbenzamide A mixture of the hydrochloride salt of Intermediate 2 (2.00g) and thionyl chloride (20ml) was heated at reflux for lh. The excess thionyl chloride was evaporated under reduced pressure. A mixture of the resulting solid and 4-bromo-3-methylaniline (1.50g) in dry pyridin (20ml) was heated at reflux for 30min. The solvent was evaporated and the residue adsorbed onto silica gel. The silica gel residue was purified by FCC eluting with System A (150:8:1) to give the title compound as a brown gum (2.82g).
T.l.c. System A (100:8:1) Rf 0.30 Intermediate 46 (4Acetvlphenyl)boronic acid n-Butyllithium (81.6ml) was added dropwise to a stirred solution of 2-(4-bromophenyl)-2-methyl- 1,3 -dioxolane (30. 0g) in dry iliF (400ml), under nitrogen, at -750C. After a period of 1 .5h, triisopropylborate (31.2ml) was added dropwise at -750C. The reaction was allowed to warm to room temperature over a 3h period.
Hydrochloric acid (2N; 200ml) was added and the reaction was allowed to stand at room temperature overnight. The solvent was evaporated and the residue was purified by FCC eluting with ether to give a white solid which was purified by crystallisation from water (200ml) to give the title compound (14.52g) as a white crystalline solid, m.p. 268-2700C.
Intermediate 47 4-(Hvdroxvmethvl)-2-methvlbenzeneboronic acid n-Butyl lithium (1.67M in hexane, 133ml) was added dropwise under nitrogen at -65 to -60 to a stirred solution of Intermediate 33 (18.94g) in dry THF (500 ml) over 30 min.
ARer Ih at -65 , triisopropylborate (65ml) was added at -60 to -65 over 30 min. The reaction was stirred at 230 for 1h and then stood at 230 for 7 days. The mixture was evaporated, treated with aqueous 2N sodium hydroxide (200ml) and extracted with ethyl acetate (2x200ml). The organic extracts were discarded and the aqueous phase acidified to pHl by the addition of conc. hydrochloric acid. The solution was extracted with ethyl acetate (4x200ml) and the combined, dried organic extracts were evaporated to give the crude title compound as a cream foam (11.02g).
A portion of this (2.00g) was heated to reflux in water (8ml) and decanted from the heavy yellow oil. The liquid was re-heated and decanted from the oil, and this process repeated twice more. On cooling the title compound crystallised as an off-white tacky solid (221mg).
T.l.c. ether:acetic acid (99:1) major product Rf 0.61.
Intermediate 48 1-[4'-[Bis(phenylmethyl)amino]-2-methyl[,1'-biphenyl]-4-yl]ethanone 4-Bromo-3-methylacetophenone (3.165g) and Intermediate 6 (5.189g), were treated according to the method of Intermediate 35. Purification by by FCC eluting with hexane then hexane:dichloromethane (1:1) gave the title compound as a pale yellow solid (5.3g), m.p. 145-1460C.
Intermediate 49 1-(4'-Amino-2-methyl[l * 1 '-biphenvl]-4-vl!ethanone Intermediate 48 (4.5g) was dissolved in 2-methoxyethanol (150 ml) and added to a pre-reduced suspension of palladium oxide on carbon (10%, 2.25g) in 2-methoxyethanol (150 ml) and hydrochloric acid (5N; 2 ml), and stirred under 1 atmosphere of hydrogen for 2h. The catalyst was filtered through celite, and the solvent evaporated in vacuo to give a light brown oil. This oil was preadsorbed onto silica [Merck Art. 7734, 5g] and the residue purified by SPC eluting with System D (1:3 to 2:5) to give the title compound (1.3g).
T.l.c. System D (2:5) Rf 0.45.
Intermediate 50 5-Bromo-3H-benzofuran-2-one A mixture of 5-bromo-2-methoxybenzeneacetonitrile (2.0g) and sulphuric acid (50%; 20ml) was reflux for 16h, diluted with water (40ml) and extracted with ethyl acetate (2x100ml). The dried extract was evaporated to leave the intermediate methoxybenzeneacetic acid as a white solid (1.85g). The solid in dichloromethane (40ml) at -78" was treated with boron tribromide (1M in dichloromethane 25ml) dropwise and allowed to warm to room temperature. The solution was stirred for 2h and treated dropwise with water (50ml) (cautiously).The mixture was extracted with dichloromethane (2x50ml) and the dried extract was evaporated to leave a white solid.
The solid was treated with boiling toluene (30ml), filtered and the toluene phase was evaporated. The residue was purified on a column of silica eluting with System C (4:1) to give the title compound as a beige solid (750mg) m.p. 147-148"C.
Intermediate 51 Methyl 4'-[[3-[3-(dimethylamino)-1-propynyl]-4-methoxybenzoyl]amino][1,1'-biphenyl] -4-carboxylate A suspension of the hydrochloride salt of Intermediate 1 (3.03g) in thionyl chloride (7.37ml) was heated at reflux for 5 min. The solution was evaporated and the residue co-evaporated with toluene (2x20ml). A mixture of the residue and methyl 4'-amino[1,1'-biphenyl]-4-carboxylate (2.54g) in DMF (SOml) and pyridine (50ml) was heated to 100" under nitrogen. A further quantity of DMF (50ml) was added and the reaction mixture heated at 100 , under nitrogen for 4h.The cooled solution was evaporated and treated with aqueous saturated sodium bicarbonate (1 00ml). The solid was filtered off, dried in vacuo, and dissolved in refluxing ethanol (3 litres). The insoluble material was filtered off and the filtrated adsorbed onto silica (Merck 9385) and purified by FCC using gradient elution with ethyl acetate:ethanol (9:1) to System E (80:20:1) to give an orange solid (2.8g). The solid was crystalised from ethanol:THF (2:1) to give the title compound (1.54g). m.p. 234 - 237 .
Intermediate 52 2-Methoxyethyl 4-bromo-3-methylbenzoate 4-bromo-3-methylbenzoic acid (10.0g) was treated with 2-methoxyethanol (100ml) and concentrated sulphuric acid (7.45ml) and the solution stirred at 100 C under nitrogen for 24h. When cool, the solution was evaporated, brought to pH9 with aqueous sodium bicarbonate (8%w/w, 300ml) and anhydrous sodium carbonate, and extracted with ethyl acetate (3x300ml). The dried, combined organic extracts were evaporated, adsorbed onto silica gel (Merck 7734, 60ml) and purified by FCC eluting with hexane:ethyl acetate:acetic acid (193:5:2) to give a pale brown-yellow oil (8.73g).This oil was adsorbed onto silica gel (Merck 7734, 55ml) from hot ethanol (250ml) and purified by SPC eluting with the same solvent as above to give the title compound as an orange-brown light oil (8.58g).
T.l.c. hexane ethyl acetate:acetic acid (89:10:1), Rf0.37.
Intermediate 53 2-Methoxyethyl 4'-[bis(phenylmethyl)amino]-2-methyl[1,1'-biphenyl]-4-carboxylate A hot mixture of Intermediate 52 (1.72g) and Intermediate 6 (2.0g) in DME (50ml) was added to a solution of anhydrous sodium carbonate (0.94g) in water (25ml). Tetrakis (triphenylphosphine)palladium (0) (0.277g) was added and the mixture stirred at reflux under nitrogen for 6h. The cool mixture was evaporated, the residue absorbed onto silica gel (Merck 7734, 25ml) from hot ethanol (250ml), and purified by FCC eluting with hexane:ethyl acetate (9:1) to give the title compound as a cream/yellow solid (2.57g) m.p.
91930.
Intermediate 54 2-Methoxvethvl 4'-amino-2-methyl r 1 '-bishenvll-4-carboxylate A solution of Intermediate 53 (2.45g) in DMF (80ml) was added to a pre-hydrogenated mixture of 10% palladium-on-carbon (1.0g) and DMF (30ml) and the mixture hydrogenated at room temperature and pressure for 54h until uptake ceased. The catalyst was filtered off and the filtrate evaporated. The residue was treated with ethanol (100my), filtered, and the filtrate adsorbed onto silica gel (Merck 7734, 7g). Purification by FCC eluting with ethyl acetate:hexane (1:2) gave the title compound as cream-coloured crystals (1.38g), m.p. 72-75 .
Intermediate 55 2-(Dimethylamino)ethyl 4-bromo-3-methvlbenzoate 4-bromo-3-methylbenzoic acid (8g) was treated with thionyl chloride (12ml) and stirred at reflux for 2h. When cool, the solution was evaporated and then co-evaporated with toluene (2x15ml). The remaining liquid was treated with 2-dimethylaminoethanol (4.lml), followed by pyridine (lOml), under ice-cooling, and then the reaction mixture was allowed to reach room temperature and stirred for a further 2h. Aqueous sodium bicarbonate (8%, 20ml) was added and the resultant solution was then evaporated down to a small volume. The solution/slurry was then acidified with hydrochloric acid (2N; loom) and extracted with ethyl acetate (2x100ml). The organic extracts were discarded and the aqueous component basified with sodium bicarbonate (8%).The resultant aqueous solution was extracted with ethyl acetate (3x250ml), and the combined, dried extracts were evaporated in vacuo to give the title compound as a slightly impure oil.
Purification by FCC eluting with System A (97:3:0.3) afforded the title compound as a pale yellow oil (5.46g).
Analysis Found: C,50.3; H.5.7; N,4.9; Br, 27.7 C,2H,6BrNO2 requires C,50.4; H,5.6; N,4.9; Br, 27.9%.
Intermediate 56 (2s2-Dimethvl-1.3-dioxolan-4-vl!methyl 4-bromo-3-methvlbenzoate A slurry, of 2,2-dimethyl-1,3-diozolane-4-methanol (0.963ml), 4-bromo-3-methylbenzoic acid (2g), 4-pyrrolidinopyridine (0.22g) and 4-[2-[(cyclohexylcarbonimidoyl) amino]ethyl]-4-methylmorpholinum 4-methylbenzenesulphonate (5.5g) in dry dichloromethane (50ml) was stirred vigourously at room temperature, under nitrogen, for 72h. The mixture was evaporated in vacuo to dryness and then sodium bicarbonate was added (8%, 80ml). The aqueous solution was extracted with ether (3x100ml), and the combined, dried organic extracts were evaporated onto silica gel (Merck Art 7734).
Purification by FCC eluting with System C (9:1) gave the title compound as a yellow oil (1:53g).
T.l.c. System C (9:1) Rf0.15 Intermediate 57 2,3-Dihydroxypropyl 4-bromo-3-methylbenzoate Intermediate 56 (1.27g) was dissolved in THF (50ml) containing hydrochloric acid (2N; 20ml) and stirred at room temperature for 80h. Sodium carbonate (8%, 80ml) was added and the resultant solution was evaporated in vacuo. The remaining solution was extracted with ethyl acetate (3x150ml) and the combined, dried extracts were evaporated in vacuo to give an oil. This oil was purified by FCC eluting with System C (15:85) to give the title compound as a colourless oil (0.858g).
T.l.c. (ether) Rf0.3.
Intermediate 58 (+1-) 2-Methoxe-l-metherlethvl 4-bromo-3-methvlbenzoate A mixture of (+) 2-methoxy-1-methylethanol (100ml), 4-bromo-3-methylbenzoic acid (10.0g), and concentrated sulphuric acid (7.45ml) were stirred at 90-100 under nitrogen for 18h. The solution was evaporated and the residue was basified to pH8 by the addition of aqueous saturated sodium bicarbonate (300ml). The mixture was extracted with ether (5x200ml) and the combined, dried organic extracts were evaporated. The residual oil was purified by FCC, eluting with ether acetate:hexane (1:49) to give the crude title compound (7.67g). A portion of this (4.0g) was purified by SPC (Merck 7729) eluting with ethyl acetate:hexane (25:975) to give the title compound as a light orange oil (3.4g).
Analysis Found: C,50.3; H,5.3; Br, 27.9 C,2H,5BrO requires C, 50.2; H, 5.3; Br, 27.8% Intermediate 59 [4-rr3 -[3 -(Dimethylamino)propyl]-4-methoxybenzoyl]amino]-3 -methvlphenvliboronic acid A solution of n-butyl lithium (1.68M; 6mi) in hexane was added dropwise to a solution of Intermediate 45 (1.4g) in THF (20ml) at -78 for 1h, warmed to 0 , and re-cooled to -78 .
Triisopropylborate (1.88g) was added dropwise and the solution was stirred at -78 for 1h and at room temperature for 2h. Water (50ml) was added and the mixture was extracted with dichloromethane (4x75ml). The dried extract was evaporated and the residue was purified by FCC eluting with System F (190:10:1) followed by (90:10:1) to give the title compound as a white foam (220mg).
T.l.c. System F (90:10:1), Rf 0.25 Intermediate 60 2-Methoxvethvl 4-io do-2-methoxvbenzoate A solution of 4-iodo-2-methoxybenzoic acid (900mg) in 2-methoxyethanol (loll) was treated dropwise with sulphuric acid (18N; 0.1ml) and heated at 100 for 22h. The solution was basified with aqueous sodium bicarbonate (1M) and evaporated. The residue was partitioned between aqueous sodium bicarbonate (1N; 50ml) and ethyl acetate (3x50ml). The dried extracts was evaporated to give an oil which was purified by FCC eluting with System C (4:1) followed by (3:2) to give the title compound as a colourless oil (l.Og).
T.l.c. System C (1:1), Rf 0.45 Intermediate 61 4-Bromo-N-(methanesulphonyl)-3-methylbenzamide DMF (5 drops) was added to a solution of 4-bromo-3-methylbenzoic acid (2.0g) and oxalyl chloride (1.06g) in dichloromethane (50ml) under nitrogen. The solution was stirred until effervescence ceased (1h). and was evaporated. The residue was treated with methanesulphonamide (940mg) and the mixture was heated at 130C for 3h. During this time the solid mixture liquified and gradually resolidified to leave an orange solid. The solid was purified by FCC eluting with ether followed by ethyl acetate to give the title compound as a white foam (405mg).
Analysis Found - C,32.9; H,3.2; N.4.0 C9H10BrNO3S.2H2O requires C,32.9; H,4.3; N, 4.3% Intermediate 62 2-Hydroxv-4-iodobenzenemethanol A solution of borane in THF (1M, 50ml) was added dropwise to a solution of 2-hydroxy-4-iodobenzoic acid (5.0g) in THF (50ml) under nitrogen. The solution was stirred at room temperature for 1h and at reflux for Ih. The cooled solution was treated cautiously with hydrochloric acid (2N; 50ml) and THF was evaporated in vacuo. The resulting mixture was extracted with dichloromethane (2x100ml) and the dried extract was evaporated.The residue was crystallised from toluene to give the title compound as a beige solid (2.7g). m.p. 129-131 Intermediate 63 7-Iodo-4H- 13 -benzodioxin A mixture of sodium hydride (80% disp; 350mg) and DMF (lOml) under nitrogen was treated slowly with a solution of Intermediate 62 (0.5g) in dichloromethane (Sml). The mixture was heated at 800 for 25min, cooled, and treated dropwise with water (50ml).
The resulting emulsion was extracted with dichloromethane (2x100ml) and the dried extracts was evaporated to leave an orange oil. The oil was purified by FCC eluting with System C (9:1) to give the title compound as a white solid (125mg).
T.l.c. System C (3:1) Rf 0.6.
Intermediate 64 4-(Bromomethyl!4'-nitro- 1.1 '-biphenyl To a solution of 4-methyl-4'-nitro[l,l'-biphenyl] (2g) in carbon tetrachloride (40ml) was added to a trace of benzoyl peroxide and N-bromosuccinimide (i.67g). The mixture was heated under reflux and irradiated with white light (150 Watts) for 30min. The mixture was filtered, the residue washed with carbon tetrachloride (loll) and the combined filtrate and washings evaporated to give a yellow solid consisting of the title compound (2.75g).
T.l.c. cyclohexane:ethyl acetate (15:1) Rf0.38.
Intermediate 65 4-(1H-Imidazol-1-ylmethyl)-4'-nitro-1,1'-biphenyl To a solution of imidazole (0.35g) in dry DMF (lOml) was added sodium hydride (0.154g of an 80% dispersion in oil). After 10 min, a solution of Intermediate 64 (1.5g) in dry DMF (5ml) was added. The solution was stirred at room temperature for 3.5h and evaporated to dryness. The residue was mixed with ethyl acetate (200ml), washed with water (2x50ml) and extracted with 2N hydrochloric acid (3x100ml). The combined extracts were washed with ether (2x50ml) and the pH of the solution adjusted to 11 with 40% aqueous sodium hydroxide. The mixture was extracted with dichloromethane (4x75ml), the combined extracts dried then filtered and the filtrate evaporated to dryness to give the title compound (0.919g) as a yellow solid.
Intermediate 66 4'-(1H-Imidazol-1-ylmethyl)-[1,1'-biphenyl]-4-amine A solution of Intermediate 65 (0.708g) in acetic acid (5ml) containing 10% palladium on carbon (0.3g) was hydrogenated at atmospheric pressure and room temperature for 3h.
The mixture was filtered and the combined filtrate and washings were evaporated to give a yellow crystalline product which was triturated with ether to give the title compound as a cream-coloured solid (0.488g).
T.l.c. System B (10:1) Rf 0.26 Intermediate 67 3-(4-Bromo-3-methylphenyl)-5-methyl-1,2,4-oxadiazole A solution of sodium methoxide (1.93g) in methanol (ism) was added dropwise over 10 min to a solution of hydroxylamine hydrochloride (2.48g) in methanol (30ml). The mixture was stirred for Oh at 20 and was then filtered. 4-Bromo-3-methylbenzonitrile (7g) was then added to the filtrate, and the mixture heated to reflux for 18h. The solvent was then evaporated giving a grey solid, a portion of which (2.2g) was dissolved in acetic anhydride (6ml) and heated to 80" for 18h. The reaction was cooled and was poured into water (100ml).The solid was separated, collected and recrystallised from isopropanol (20ml) giving the title compound as colourless microcrystals (896mg) m.p.
78 .
Intermediate 68 2'-Methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-carboxylic acid A mixture of 4-carboxyphenylboronic acid (1S0mg), Intermediate 67 (228mg), sodium carbonate (412mg) and tetrakis(triphenylphosphine)palladium (0) (21mg) in 1:1 aqueous DME (20ml) was heated at reflux under nitrogen for 18h. The mixture was allowed to cool, acidified with 2N HCl and. then extracted with ethyl acetate (2x40ml). The dried extracts were evaporated to give a cream-coloured solid (285mg). This was recrystallised from isopropanol (5ml) giving the title compound as a fawn solid (1 65mg).
mp. 229-231 Intermediate 69 5 -(4-Bromo-3 -methvlphenvl)-3 -methvl-l 2,4-oxadiazole Sodium metal (602mg) was added to a suspension of molecular sieves (4A) in absolute ethanol (30ml) under nitrogen at 20 . ARer 15min N-hydroxyethanimidamide (1.94g) was added. Stirring was maintained for Oh whereupon methyl 4-bromo-3-methylbenzoate (lg) was added. The mixture was heated to reflux for 1.5h, then filtered and the filtrate evaporated to dryness. The residue was dissolved in water (75ml) and extracted with ethyl acetate (2x75m1) and the dried extracts evaporated to give the title compound as a colourless solid (856mg) m.p. 75-77 .
Example 1 (a) N-(4'-Acetvl [1,1 '-biphenvll-4-vl)-3 -[3 -(dimethvlamino)propvll-4-methoxvbenzamide A solution of the free base of the product of Example 4 (158mg) in dry 1,4-dioxan (9ml) was treated with activated manganese (IV) oxide (157mg) and the mixture stirred at reflux for 2h. The mixture was filtered and the filter cake washed with hot ethanol. The combined filtrate and washings were evaporated and the residue purified by SPC eluting with System A (945:50:5 934:60:6) to afford a solid which was twice crystallised from ethanol to give the title compound (36mg) as fine white crystals, T.l.c. (System A 923:70:7) Rf0.19 Analysis Found: C,75.2; H,7.0; N,6.2.
C27H30N2O3 requires C,75.3; X7.0; N,6.5%.
Similarly prepared was: (b) N-(4'-Acetyl[1,1'-biphenyl]-4-yl)-3-[2-(dimethylamino)ethyl]-4-methoxybenzamide as a cream-coloured solid (131mg) m.p. 236-2400.
Analysis Found: C,75.05; H,6.8; N,6.7; C26H28N2O3 requires C,75.0; H,6.8; N,6.7%.
From the product of Example 8 (281mg).
Example 2 4'-[[3 -[3 -(Dimethylamino)propvll-4-methoxybenzovl] amino] [1.1 '-biphenyl] 4- carboxylic acid maleate A mixture of 4-boronobenzoic acid (181mg) and Intermediate 20 (427mg) in DME (lOml) was treated with a solution of sodium carbonate (1 16mg) in water (Sml), followed by tetrakis(triphenylphosphine)palladium (0) (50mg), and the stirred mixture was heated at reflux under nitrogen for 4h. The mixture was evaporated, and the residue purified by FCC using gradient elution with System A (78:20:2 to 56:40:4) to afford a white solid (271mg). A portion ofthe solid (241mg) was treated with maleic acid (69mg) and ethanol (20ml) was added gradually at reflux until the solids dissolved.On cooling, the white solid was collected to give the title compound (143mg) as fine white crystals, m.p.
189-1930.
Analysis Found: C,65.7; H,5.8; N,5.0.
4.C4H2O4 requires C,65.7; H,5.9;l N,5.1%.
C C H 0 Similarly prepared was: Example 3 3-[3-(Dimethylamino)propyl]-N-(4'-formyl-2'-methyl[1,1'-biphenyl]-4-yl) -4-methoxvbenzamide. ethanedioate (1:1) (314mg) as a colourless, crystalline solid, m.p.
177.5-180.5 .
Analysis Found: C,66.85; H,6.2; N,5.3.
C27H30N203.C2H204 requires C,66.9; H,6.2; N,5.4%.
From Intermediate 20 (1.174g) and Intermediate 28 (514mg). After 7h, the reaction mixture was cooled, diluted with 2N aqueous sodium carbonate (100ml), and extracted with dichloromethane (3x100ml). The combined extracts were dried, evaporated and purified by SPC using System A (95:5:0.5) followed by (90:10:0.5) as eluent, to give the free base of the title compound (1.25g) as a viscous gum, which still contained some ethanol. T.l.c. (System A 95:5:0.5) Rf 0.15. A sample (314mg) of this material in ethyl acetate (15ml) was added slowly to a boiling solution of anhydrous oxalic acid (74mg) in ethyl acetate (35ml). After cooling, the solid was collected, washed with ethyl acetate, and dried under high vacuum at 700, to give the title compound.
Example 4 3-[3-(Dimethylamino)propyl]-N-[4'-(1-hydroxyethyl)[1,1'-biphenyl]-4-yl] -4-methoxybenzamide hydrochloride A mixture of Intermediate 2 (300mg) in thionyl chloride (0.7ml) with a catalytic quantity of dry DMF (1 drop) was heated at reflux for 15min. The reaction mixture was cooled and the thionyl chloride was evaporated. The residue was re-evaporated with dry toluene (2x7ml) to leave a buff coloured solid. A solution of the solid and Intermediate 13 (270mg) in dry pyridine (5ml) was stirred at room temperature for 5h. The reaction mixture was then added to aqueous sodium carbonate (2M; 25ml) and extracted with dichloromethane- isopropanol (9:1, 4x20ml). The combined extracts were dried, filtered, and evaporated to give a solid.The solid was adsorbed on silica and purified by FCC eluting with System A (150:8-: 1) to give recovered 4'-amino-amethyl-[l;l'-biphenyl]-4-methanol (49mg) and then with System A (100:8:1) to give a white solid (385mg). A solution ofthe solid in ethyl acetate:methanol (5:1, 60ml) was treated with excess ethereal hydrogen chloride. The resultant solid was filtered off, washed with dry ether, and dried under vacuum to give the title compound (280mg) as an off-white crystalline solid, m.p. 242-244 .
T.l.c. System A (50:8:1) Rf 0.28.
Similarly prepared were: Example 5 3-[3-(Dimethylamino)propyl]-N-[2'-(1-hydroxyethyl)[1,1'-biphenyl]-4-yl] -4-methoxvbenzamide hvdrochloride (455mg) as a white crystalline solid m.p. 224227o.
T.1.c. System E (85:15:1) Rf0.14.
From Intermediate 2 (400mg) and Intermediate 9 (360mg) with a reaction time of 36h.
Extraction was carried out using dichloromethane and purification was by FCC eluting with System E (85:15:1).
Example 6 3-[3-(Dimethylamino)propyl]-N-(4'-ethyl[1,1'-biphenyl]-4-yl)-4-methoxybenzamide (487mg) as white crystalline needles, m.p. 200- 2020.
T.l.c. System A (100:8:1) Rf0.25.
From Intermediate 2 (529mg) and Intermediate 14(a) (440mg) with a reaction time of 72h. Extraction was carried out using chloroform and purification was by FCC eluting with System E (90:10:1) to give a white crystalline solid. The solid was further purified by crystallisation from isopropyl acetate (40ml) to give the title compound as a free base.
Example 7 4'-[[3-[3-(Dimethylamino)propyl]-4-hydroxybenzoyl]amino][1,1'-biphenyl]-4 carboxylic acid A hot solution of 4-boronobenzoic acid (678mg) and Intermediate 21 (1.54mg) in DME (70ml) was treated with a solution of sodium carbonate (692mg) in water (35ml), followed by tetrakis(triphenylphosphine)palladium (0) (189mg) and stirred under nitrogen at reflux for 3h. The mixture was evaporated and purified by FCC eluting .with System A (67:30:3 to 50:45:5) to afford a solid. The solid was triturated with ethanol (40ml) and the precipitate filtered off to give the title compound (837mg) as fine white crystals, m.p.
278-280 .
Analysis Found: C,70:8; 11,6.0: N,6.35 C25H26N2O4.0.35 H2O requires: C,70.7; H,6.3; N,6.6% Water assay Found: 1.47% w/w H20= 0.35 mole.
Example 8 3-[2-(Dimethylamino)ethyl]-N-[4'-(1-hydroxyethyl)[1,1'-biphenyl]-4-yl]-4 methoxvbenzamide A suspension of the free base of Intermediate 19 (945mg) in thionyl chloride (7ml) was treated with dry DMF (1 drop) and heated at reflux for 1h. The solution was evaporated and the residue co-evaporated with toluene (4x10ml). The residue was treated with Intermediate 13 (903mg), followed by dry pyridine (10ml), and heated at 80-100 for 1h under nitrogen. The cooled solution was evaporated and treated with aqueous saturated sodium bicarbonate (50ml). The solid was filtered off and air-dried for 30min to give solid (I). The filtrate was extracted with ethyl acetate (7x 150ml), and the combined, dried organic extracts were evaporated. The residue was mixed with solid (I) and adsorbed from hot ethanol onto silica gel (Merck 7734).The resultant silica gel was applied as a plug to a flash column and gradient elution with System A (945:50:5 to 934:60:6) afforded a solid (340mg). A portion of this solid (80mg) was crystallised from ethanol to give the title compound (30mg) as a cream-coloured solid.
T.l.c. System A (89:10:1) Rf0.19.
Analysis Found: C,74.35; H,7.2; N,6.55 C26H30N203 requires C,74.6; H,7.2; N,6.7%.
Example 9 4'-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amino]-N,N-dimethyl [1,1'-biphenyl]-4-carboxamide A solution of Intermediate 2 (1.74g) in dry TEIF (40ml) and dry DMF (40ml) was treated under nitrogen with triethylamine (2.05ml), followed at -10 to -50 by methanesulphonyl chloride (0.57ml). After 1.5h, Intermediate 11 (1.885g) was added and after 2h the mixture was stirred at room temperature overnight, then heated at reflux for 1h. The mixture was evaporated to give a yellow solid, sodium bicarbonate (8%, 70ml) was added and the mixture extracted with ethyl acetate (4x50ml). The combined, dried organic extracts were evaporated to give yellow crystals which on recrystallisation from ethyl acetate gave cream crystals (1.2g). The crystals were recrystallised from ethyl acetate (70ml) to give a cream powder which was dried under vacuum at 500 to give the title compound (0.79g), m.p. 180-1820.
T.l.c. System A (824:160:16) Rf 0.56.
Example 10 4'-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amini][1,1'-biphenyl] -4-carboxamide maleate A solution of Intermediate 2 (670mg) in dry T11F (15ml) and dry DMF (15ml) was treated under nitrogen with triethylamine (0.79ml) and followed at -15 to - 100 by methanesulphonyl chloride (0.22ml). After 2h. Intermediate 12 (600mg) was added, and after 2h, the mixture was stirred at 230 for 3 days.The mixture was evaporated and the residue treated with aqueous saturated sodium bicarbonate (35ml). The precipitate was filtered off, air-dried for 30 min, and then dried in vacuo over phosphorus pentoxide for 1 h. The solid was adsorbed from ethanol onto silica gel (Merck 7734, 15g) and the resultant silica gel applied as a plug to a flash column. Elution with System A (945:50:5 to 890:100:10) afforded firstly recovered 4'-amino[l,l'-biphenyl]-4-carboxamide and secondly the free base of the title compound (412mg) as a white solid. T.l.c. System A 89:10:1) Rf 0.09. A mixture of the free base (376mg) and maleic acid (121mg) was dissolved in hot ethanol (130ml), filtered, and on cooling the title compound (294mg) crystallised as fine white crystals.
Analysis Found: C,65.7; H,6.1; N,7.5.
C26H29N3O3.C4H4O4 requires C,65.8; H,6.1; N,7.7%.
n.m.r. (DMSO-d6) 6 1.94 (2H,m), 2.68 (2H,t), 2.78 (6H,s), 3.09(2H,m), 3.92 (3H,s), 6.05 (2H,s), 7.43 + 8.06 (2H, 2 xbr.s), 7.17 + 7.75-8.0 (11H,m), 10.25 (lH,s).
Similarly prepared was : Example 11 N-[4'-(Aminosulphonyl)[1,1'-biphenyl]-4-yl]-3-[3-(dimethylamino)propyl]-4methoxvbenzamide maleate (140mg) as cream-coloured crystals, m.p. 226-2280, Analysis found: C,59.7;H,5.7;N,7.1.
C25H29N3O4S.C4H4O4 requires C,59.7; H,5.7; N,7.2% From Intermediate 2 (0.566mg) and 4'-Amino[l,l'-biphenyl]4-sulphonamide (0.587mg).
Except that on evaporation of the reaction mixture the residue was adsorbed from refluxing methanol onto silica gel (Merck 7734) and purified by SPC eluting with System A (945:50:5 to 89:10:1).
Example 12 3-[3-(Diethylamino)propyl]-N-(4'-nitro[1,1'-biphenyl]-4-yl)-4-methoxybenzamide hvdrochloride A stirred suspension of Intermediate 2 (500mg) in dry THF (20ml) and dry DMF (20ml) was treated under nitrogen at 230 with triethylamine (584mg) and followed at -50 to -100 by the addition of methanesulphonyl chloride (0.16mol). After 2h, 4'-nitro[l,l'- biphenyl]-4-amine (384mg) was added and after 2h the mixture was stirred at 230 for 24h.
The mixture was heated at reflux for 16h, cooled, and evaporated. The residue was treated with aqueous saturated sodium bicarbonate (80ml), extracted with ethyl acetate (3x80ml), and the combined, dried organic extracts were evaporated. The residue was purified by FCC eluting with System A (945:50:5 to 912:80:8) to afford a solid a solution of ethanol (20ml) was acidified with ethanolic hydrogen chloride to pH1 and the precipitate collected to give the title compound (168mg) as fine yellow crystals.
T.l.c. System A (945:50:5) Rf 0.22.
Analysis Found: C,64.0; H,6.0; N,9.0.
C27H27N3O4.HCl.0.08C2H5OH requires C,63.8; H,6.1; N,8.9%.
Example 13 3-[3-(Dimethylamino)propyl]-N-[4'-fluoro[1,1'-biphenyl]-4-yl]-4-methoxybenzamide maleate A mixture of the free base of Intermediate 5 (1.0g), 4-fluoro[1,1'-biphenyl]-4-amine (0.94g), tri-n-butylamine (2.4ml) and dichlorobis(triphenylphosphine)palladium (11) (0.20g) in DMF (2ml) was heated at 120 , with stirring, under carbon monoxide for 18h.
The mixture was poured into aqueous 8% sodium bicarbonate (50ml), extracted with ethyl acetate (2x40ml), and the combined, dried organic extracts were evaporated. The residual yellow-brown solid was purified by SPC eluting with System A (945:50:5) to yield a cream solid (0.46g). This solid was recrystallised from ethanol (lOml) to give the free base of the title compound (0.28g) as white crystals. This was dissolved in hot ethanol and maleic acid (85mg) in warm ethanol (2ml) was added. The resultant solution was evaporated and the white solid residue was recrystallised from ethanol (2ml) to give the title compound (0.27g) as white crystals, m.p. 165-166 .
Analysis found C,66.5;H,5.9;N,5.2.
C23H,7FN2O2.C4H4O4 requires C,66.7;H,6.0;N,5.4% Similarly prepared were: Example 14 (a) 3-[3-(Dimethylamino)propyl]-N-[4'-[(dimethylamino)sulphonyl] [1.1 '-biphenv!l 4-vliA-methoxvbenzamide maleate (61mg), m.p. 140-141.
Analysis Found: C,60.9; H,6.1; N,6.75.
C27H33N3O4S.C4H4O4 requires C,60.9; H,6.1; N,6.9%.
From the free base of Intermediate 5 (868mg) and Intermediate 15 (750mg) with purification by SPC using gradient (967:30:3 to 934:60:6). Elution with System A initially formed the free base of the title compound (465mg) which was used to prepare the title compound.
(b) 3-[3-(Dimethylamino)propyl]-4-methoxy-N-[4'-(methylsulphonyl)[1,1'-biphenyl] -4-yl]benzamide maleate (316mg), m.p. 173-177.5 .
Analysis Found: C,62.0; H,6.0; N,4.6; S,5.3.
C26H30N2O4S.C4H4O4 requires C,61.8; H,5.9; N,4.8; S,5.5%.
From the free base of Intermediate 5 (800mg) and 4'-(methylsulphonyl) [1,1'-biphenyl]-4-amine (618mg) with purification by SPC using gradient elution with System A (945:50:5 to 934:60:6). A portion (421mg) of the initially formed impure free base ofthe title compound (437mg) was used to prepare the title compound.
(c) N-(4'-Cyano[1,1'-biphenyl]-4-yl)-3-[3-(dimethylamino)propyl]-4-methoxybenzamide maleate (44mg), m.p. 200-202.5 .
Analysis Found: C,68.2; H,6.1; N,7.9.
C26H27N3O2.C4H4O4 requires C,68.0; H,5.9; N,7.9%.
From 4'-amino-[1,1'-biphenyl]-4-carbonitrile (493mg) and the free base of Intermediate 5 (812mg) with purification by SPC eluting with System A (956:40:4 to 934:60:6). The initially formed impure free base ofthe title compound (145mg) was used to prepared the title compound.
Example 15 4'-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amino][1,1'-biphenyl] -3-carboxamide hvdrochloride (185mg) T.l.c. System A (12:1:87) Rf0.11, Analysis Found: C,65.7; H,6.6; N,8.6.
C2611,9N3O3.HCl.0.3 311,O.0.33CH5OH requires C,65.5; H,6,7; N,8.6%.
Water assay found 1.23% H2O = 0.33 mol H2O From Intermediate 16(a) (600mg) and the free base of Intermediate 5 (902mg) with purification by SPC using gradient elution with System A (923:70:7 907:85:8). The initially formed free base of the title compound (493mg) was dissolved in hot ethanol (35ml), treated with ethanolic hydrogen chloride (2ml) and cooled to give the title compound.
Example 16 3'-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amino][1,1'-biphenyl] -4-carboxamide hvdrochloride (115mg), m.p. 1450.
Analysis Found: C,64.7; H,6.8; N,8.2.
C26H29N3O3.HCl.0.3 CH3CO2C2H5 requires C,64.8; H,6.5; N,8.3%.
From Intermediate 7 (1.56g) and the free base of Intermediate 5 (2.35g) with purification by FCC eluting with System A (89:10:1). Two fractions of the impure free base of the title compound were initially formed. The initial fractions was further purified by SPC eluting with System A (89:10:1) to give a pale cream solid which was crystallised from ethyl acetate. A hot solution of the free base in refluxing ethyl acetate was added to ethereal hydrogen chloride (3ml) and the precipitate was filtered off to give the title compound.
Example 17 4'-[[3-[3-(Dimethylamino)propyl]-4-hydroxybenzoyl]amino]-N,N-dimethyl r 1. 1 '-biphenvll-4-carboxamide Sodium hydride (0.470g, dispersion in oil) was washed under nitrogen with hexane, treated with dry DMF (6ml) and then ethanethiol (1.06ml) in dry DMF (6ml) was added dropwise over Smin. After 1h, DMF (2ml) was added, followed by a solution of the product of Example 9 (0.658g) in dry DMF (8ml). The solution was heated at 1500 under nitrogen for 18h and then at 2000 for 2h. The cooled mixture was acidified to pHi with 2N hydrochloric acid and basified to pH8 with saturated sodium bicarbonate. The mixture was extracted into ethyl acetate (20x1 00mi) and the combined dried organic extracts were evaporated.The residue (500mg) was adsorbed from refluxing methanol (SOOml) onto silica gel (Merck 9385) and this was purifed by FCC eluting with System A (18.4:1.4:0.14 to 17.5:2.5:0.75) to give the title compound (296mg) as a white power, m.p. 235.0-237.5 .
T.l.c. System A (175:2:5:0.25) Rf 0.48.
Example 18 N-(4'-Cyano[1,1'-biphenyl]-4-yl)-3-[3-(dimethylamino)propyl]-4-methoxybenzamide hydrochloride The combined mother liquors obtained from recrystallisation of the product of Example 14(c) were evaporated and then treated with aqueous saturated sodium bicarbonate (50ml). The mixture was extracted with ethyl acetate (4x80ml) and the combined, dried organic extracts were evaporated. The residue in ethanol (2ml) was acidified to pH2 with ethanolic hydrogen chloride and on cooling, the precipitate was collected to give the title compound (27mg) as fine white crystals, m.p. 222-225.5 .
Analysis Found: C,69.4; H,6.3; N,9.2.
C25H27N3O2. HCI requires: C,69.4; H,6.3; N,9.3% Example 19 4'-[[[3-[(Dimethylamino)propyl]-4-methoxyphenyl]methyl]amino]-&alpha;-methyl [1,1'-biphenyl]-4-methanol A cooled (ice-bath) suspension of lithium aluminium hydride (0.493g) in dry THF (lOml) was treated dropwise with a solution of the free base of the product of Example 4 (1 .88g) in dry THF (50ml). The reaction mixture was then heated at reflux for 1.5h. The reaction mixture was carefully treated with hydrochloric acid (2M; 75ml) and then basified with aqueous sodium hydroxide (5M; 35ml). The aqueous phase was extracted with chloroform (3x100ml).The combined extracts were dried, filtered and evaporated to give a light brown gum which was purified by FCC eluting with System E (95:5:1) to give the title compound (1.431g) as an off-white solid, m.p. 148-152 .
Analysis Found C,77.2; H,8.4; N, 6.5; C27HN2O2 requires C,77.5; H,8.2; N,6.7% Example 20 (a) 3-[3-(Dimethylamino)propyl]-4-methoxy-N-(4'-methoxy[1,1'-biphenyl]-4-yl) benzamide A stirred mixture of the hydrochloride salt of Intermediate 2 (1.095g) in thionyl chloride (lOml) was heated at 90-100 until gas evolution ceased (20min). The solution was cooled and evaporated to dryness to give a solid. A solution of this solid in dry dichloromethane (20ml) was diluted with dry pyridine (20ml) and treated with Intermediate 29 (731mg). The resulting suspension was stirred at room temperature for 17h and then heated at reflux for 3h. Water (semi) was added, with vigorous stirring for 30min.After addition of 2N aqueous sodium carbonate (Sml), the mixture was evaporated to dryness and then purified by FCC eluting with System F (95:5:0.5) to give the major product (700mg) as a cream coloured solid. Crystallisation from toluene gave the title compound (623mg) as a cream coloured crystalline solid, m.p. 198.5-200.5 .
T.l.c. System F (95:5:0.5) Rf 0.26.
Similarly prepared were: (b) 3-[3-(Dimethylamino)propyl]-N-[3'-hydroxy-4'-(hydroxymethyl)[1,1'-biphenyl] -4-yl[-4-methoxybenzamide (168mg) as a cream crystalline solid, m.p. 171-1730.
Analysis Found: C,71.0; H,6.95; N,6.1; C26H30N204.0.2 (CH3CO2C2H5) requires C,71.2; H,7.0; N,6.2% From the hydrochloride salt of Intermediate 2 (369mg) and Intermediate 22 (279mg) using DMF as reaction solvent. Purification by SPC eluting with System A (90:10:1) afforded the title compound (274mg) as a glass which was recrystallised from ethyl acetate.
(c) 4'-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amino]-3-hydroxy F 1.1 '-biphenyli-4-carboxylic acid (520mg).
T.l.c. System A (75:25:2.5) Rf0.19.
Analysis Found: C,67.25; H,6.75; N,5.65.
C26H28N2O5.(C2H5OH).0.5H2O requires C,66.8; X7.0; N,5.55%.
Water Analysis Found: 1.84% H2O w/w = 0.5H2O From the hydrochloride salt of Intermediate 2 (441mg) and Intermediate 10 (345mg).
The reaction mixture was heated in an oil bath (75 ) for 20h and then cooled and treated with water (lml). After vigorous stirring for lOmin, the mixture was basified to pH12 by addition of 2N aqueous sodium hydroxide (4ml) and then evaporated to dryness. The residue was purified by SPC (Merck 7729) using System A (75:25:2.5) as eluent, to give the product (573mg) as a light brown solid. Trituration with hot absolute ethanol (10ml) gave, after cooling, washing, and collection, the title compound as a pale brown solid.
Example 21 N-[3-[3-(Dimethylamino)propyl]-4-methoxyphenyl][1,1'-biphenyl]-4,4'-dicarboxamide methanesulphonate Thionyl chloride (0.14ml) was added dropwise under nitrogen to a stirred suspension of Intermediate 8(i) (396mg) in pyridine (5ml). After 1h at 23 , the solution was treated at 00 with a solution of Intermediate 27 (376mg) in pyridine (Iml) and then stirred at 230 for 20h. The mixture was treated with aqueous saturated sodium bicarbonate (40ml) and ethyl acetate (50ml), then filtered and the residue was dried in vacuo over phosphorus pentoxide. The organic layer was separated and the aqueous further extracted with ethyl acetate (4x1 00ml). The combined, dried organic layers were evaporated, treated with the above dried solid, and adsorbed from ethanol onto silica gel.The residue was purified by SPC and gradient elution with System A (89:10:1 to 87:12:1) afforded the free base of the title compound (167mg). A solution of the free base (167mg) in hot ethanol (180ml) was treated with a solution of orthophosphoric acid (76mg) in ethanol (4ml), and on cooling the free base of the title compound crystallised (117mg). A solution of the free base (117mg) in hot ethanol (1 litre) was treated with a solution of methanesulphonic acid (47mg) in ethanol (2ml) and on cooling the title compound (51mg) crystallised as cream crystals.
T.l.c. System A (89:10:1) Rf 0.06.
Analysis Found: C,60.2; H,6.3; N,7.7.
C26H29N3O3.MeSO3H.0.52H2O requires C,60.4; H,6.4; N,7.8% Water assay Found: H2O, 1.75=0.52mol H20.
Example 22 3 - [3 -(Dimethvlamino!propylJ-4-hvdroxv-N-(4'-hvdroxvr 1.1 '-biDhenvll-4-vl)benzamide A stirred mixture of Intermediate 21 (919mg), Intermediate 23 (713mg), tetrakis(triphenylphosphine)palladium (0) (138mg), and anhydrous sodium carbonate (318mg), in water (6ml) and DME (6ml) under nitrogen was heated at reflux. After 7.5h, the solution was cooled, basified with 2N aqueous sodium hydroxide (9ml), and absorbed onto silica gel (lOg). SPC (Merck 7729) using System A (90:10:1) as eluent gave a product (900mg) as a colourless glass. (T.l.c. System A (90:10:1) single spot Rf 0.17) This material was combined with that (130mg) from a previous experiment and dissolved in boiling ethyl acetate (90ml).The clear supernatant was added gradually to a boiling solution of maleic acid (337mg) in ethyl acetate (60ml). After cooling, the product was collected, washed with ethyl acetate, and dried at 700/0.4 torr to give the maleate of the title compound (1.242g) as a colourless crystalline solid, m.p. 202-204 . The title compound was recovered from the maleate by basifying its aqueous solution with 8% aqueous sodium bicarbonate (SOml) and extracting into ethyl acetate: isopropanol (9:lj (4x200ml). The combined extracts were dried and evaporated to give a colourless gum.
Crystallisation from ethyl acetate:hexane gave the title compound (683mg) as a colourless crystalline solid.
Analysis Found: C,73.25;H.6.85;N.6.85.
C24H26N2O3. 0.07 H,O requires C,73.5; H,6.75; N,7.15% Water Analysis indicates 0.07 moles H20 n.m.r. (DMSO-d6) 6 1.77 (2H,m), 2.20 (6H,s), 2.27 (2H,t), 2.63 (2H,t), 6.8-7.9 (1 iN), 10.00 (1H,s).
Example 23 N-[4'-(1-Hydroxyethyl)[1,1'-biphenyl]-4-yl]-3-[3-(methylamino)propyl]-4 methoxvbenzamide A mixture of Intermediate 16(b) (221mg) in thionyl chloride (1.5ml) was heated at reflux for 15min. The thionyl chloride was evaporated and the residue was reevaporated with dry toluene (2x10ml) to leave an off-white solid (227mg). . A solution of the solid (227mg) in dichloromethane (6ml) and dry DMF (imi) was added to a solution of Intermediate 13 (182mg) in dry pyridine (5ml). The reaction mixture was then stirred at room temperature for 72h. The reaction mixture was added to aqueous sodium carbonate (2N; 40ml), extracted with dichloromethane (4x25ml) and the combined extracts were dried, filtered and the filtrate was purified by FCC.Elution with System A (100:8:1) gave an off-white solid (152mg). The solid was further purified by crystallisation from ethyl acetate (25ml) to give the title compound (79mg) as an off-white crystalline solid m.p.
175-1780.
T.l.c. System A (50:8:1) Rf0.18.
Example 24 3-[3-(Dimethylamino)propyl]-N-[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl] -4-methoxybenzamide maleate A mixture of 4-(hydroxymethyl)benzeneboronic acid (240mg) and Intermediate 20 (618mg) in DME (15ml) were treated with a solution of sodium carbonate (176mg) in water (9ml), followed by tetrakis(triphenylphosphine)palladium (0) (73mg), and stirred at reflux under nitrogen for 5h. When cool, the mixture was evaporated, then treated with water (100ml), and extracted with ethyl acetate (5x100ml). The combined, dried organic extracts were evaporated, and the residue purified by FCC eluting with System A (945:50:5 to 923:70:7) to give the free base (545mg). A portion ofthe free base (200mg) was treated with maleic acid (72mg) followed by ethanol (8ml) and heated to reflux to effect solution. On cooling the impure title compound (149mg) crystallised.A portion (100mg) of this was crystallised from ethanol (3ml) to give the pure title compound (49mg) as fine white needles, m.p. 178-1800.
T.l.c. System A (89:10:1) Rf0.14.
Example 25 N-[[4'-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amino][1,1'-biphenyl]-4-yl] carbonyliglvcine ethyl ester maleate (1:1) To Intermediate 2 (0.52g) was added thionyl chloride (3ml) and the mixture heated on a steam bath for 5 min. The excess thionyl chloride was evaporated in vacuo and the solid residue re-evaporated with toluene (10ml). The solid was suspended in pyridine (semi) and the free base of Intermediate 25 (0.597g) added. The mixture was heated on a steam bath for 20min, the pyridine evaporated in vacuo and the residue diluted with water (20ml). Sodium carbonate anhyd. (2g) was added and the solid residue filtered and washed with water. The solid was dissolved in methanol and the solution evaporated to dryness. The residue was redissolved in methanol (70ml), the solution filtered and the filtrate evaporated to about 25ml. The solid which separated was filtered, washed with methanol and dried to give the free base ofthe title compound (0.678g) m.p. 212-213 dec. The methanolic filtrate was evaporated to dryness, the residue dissolved in ethanol (10ml) and a solution of maleic acid (0.4g) in ethanol (3ml) added. On cooling, the solid which separated was filtered, washed with ethanol and dried to give the title compound (0.147g) m.p. 178-1800.
T.l.c. System A (150:8:1) Rf0.14.
Example 26 N-[[4'-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amino][1,1'-biphenyl]-4-yl] carbonyl] glycine hydrochloride A solution of the free base of the product obtained in Example 25 (0.253g) and potassium hydroxide (0.53g of 85%) in ethanol (15ml) was heated under reflux for 1h. The ethanol was evaporated in vacuo, water (20ml) added and the solution re-evaporated to remove residual ethanol. To the alkaline solution was added 5N hydrochloric acid (1.6ml) and the neutral suspension filtered. The residue was washed with water until free of chloride then with ethanol and ether and dried to give the title compound (0.245g) m.p. 293-2950 dec.
T.1.c. (chloroform: methanol:acetic acid:water 15:5:1:1) Rf0.32.
Example 27 3-[3-(Dimethylamino)propyl]-4-methoxy-N-[4'-(methylsulphinyl)[1,1'-biphenyl]-4-yl] benzamide A stirred mixture of Intermediate 20 (587mg), Intermediate 17 (331mg), tetrakis(triphenylphosphine)palladium (0) (92mg), and anhydrous- sodium carbonate (191mg), in water (4ml) and DME (4ml) under nitrogen was heated under reflux. After 7.5h, the reaction mixture was cooled, diluted with 2N aqueous sodium carbonate (100ml), and extracted with dichloromethane (3x70ml). The combined extracts were dried and evaporated to dryness to give a solid which was purified by SPC (Merck 7729) using System A (90:10:1) as eluent, to give the major product (540mg) as a fawn coloured solid. Crystallisation from ethyl acetate (23ml) gave the title compound (476mg) as a cream coloured crystalline solid, m.p. 189.5-191.5 .
T.l.c. System A (90:10:1) Rf 0.22.
Example 28 3-[3-(Dimethylamino)propyl]-N-(4'-hydroxy[1,1'-biphenyl]-4-yl)-4- methoxybenzamide A catalytic quantity of tetrakis(triphenylphosphine)palladium (0) (84mg) was added to a degassed mixture of Intermediate 20 (550mg), Intermediate 23 (386mg) and anhydrous sodium carbonate (162mg) in DME (10ml) and water (5ml). The reaction mixture was heated at reflux for 6.5h, and then allowed to stand at room temperature for 60h, under nitrogen. The reaction mixture was basified with aqueous sodium hydroxide (2N) and purified by FCC (Sorbsil C60) eluting with System A (75:8:1) to give an off-white solid (448mg). The solid was further purified by crystallisation from isopropanol to give the title compound (319mg) as a white crystalline solid m.p. 229-2300C.
T.l.c. (System A 50:8:1) Rf 0.24.
Example 29 N-(2'-Acetyl[1,1'-biphenyl]-4-yl)-3-[3-(dimethylamino)propyl]-4-methoxybenzamide (E)-2-butenedioate (1:1) A cooled solution of the free base of the product obtained in Example 5 (900mg) in acetone (25ml) was treated dropwise with a solution of chromic acid (chromium trioxide; 300mg in water 1.12ml and conc. sulphuric acid 0.27ml), at OOC. The ice bath was removed and the reaction was allowed to warm to room temperature over a 45 min period. The reaction mixture was basified with aqueous sodium bicarbonate (1M; 30ml) and extracted with dichloromethane (4x50ml). The combined extracts were dried, filtered and evaporated to give a gum (1.1g) which was purified by FCC eluting with System A (150:8:1) to give a colourless gum (700mg).A solution of the gum (700mg) in ethyl acetate (30ml) was treated with a hot solution of fumaric acid (189mg) in methanol (2ml) and the mixture was diluted with ether (50ml). The resulting solid was filtered, washed with dry ether, and dried under vacuum to give the title compound (753mg) as a white crystalline solid.
T.l.c. System A (100:8:1) Rf0.24; Analysis Found: C,67.4; H,6.2: N,4.9.
C27H0N2O3.C4H4O4 requires C,67.5; H,6.3; N,5.1%.
Water Analysis indicates 0.3H2O.
Example 30 4'-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amino]-2-methyl[1,1'-biphenyl]-4carboxylic acid A stirred mixture of Intermediate 30 (0.718g), 4-bromo-3-methylbenzoic acid (0.432g), tetrakis(triphenylphosphine)palladium (0) (0.116g) and sodium carbonate (0.852g) in water (loll) and DME (20ml), was heated at reflux under nitrogen. After 1 8h, the reaction mixture was cooled and the reaction contents adsorbed onto silica gel (Merck Art, 7734). Purification by SPC (Merck Art. 7729) eluting with System A (73:27:2.7) gave an impure sample of the title compound which was re-columned, as before, to give pure title compound (0.489g) as an off-white solid m.p. 145-147 C.
Analysis Found: C,67.3; H,6.9: N,6.2; Cl,2.4, 27H30N2O4.H2O.0.35 HCl.0.07 CH3CO2C2H5 requires C,67.8; H.69; N,5.8; Cl,2.6% Water Assay Found: 3.74% w/w H2O= 1mol H2O Example 31 N-(4'-Acetyl[1,1'-biphenyl]-4-yl)-4-ethoxy-3-[3-(methylamino)propyl]benzamide A refluxing solution of the product obtained in Example 23 (408mg) in dry 1,4-dioxan (25ml), under nitrogen, was treated with manganese (IV) oxide (509mg) and the mixture was heated at reflux for 1.75h. The hot reaction mixture was filtered, washed with dichloromethane, and the filtrate evaporated to give an off-white solid (348mg). The solid was purified by FCC eluting with System A (100:8:1) to give an off-white solid (234mg).The solid was crystallised from isopropanol (30ml) to give the title compound (81mg) as an off-white solid m.p. 195-1960C.
T.l.c. System A (50:8:1) Rf0.33.
Example 32 N-f2'-chloro-4'-(hydroxymethvl) . '-biphenvl]A-yli-3 -[3-(dimethylamino)propyl] -$methoxvbenzamide A hot solution of Intermediate 30 (1.07g), and Intermediate 32 (0.81g), in DME (50ml), was treated with anhydrous sodium carbonate (0.63g) in water (25ml), followed by tetrakis(trip'nenylphosphine)palladium (0) (130mg), and heated at reflux under nitrogen for 6h. When cool, aqueous sodium bicarbonate was added (8%, 20ml), and the reaction mixture was evaporated to dryness. The resultant solid was purified by FCC eluting with System A (93:7:0.7) to give the title compound (918mg). This was re-purified by SPC eluting with the same eluent as before to give the title compound as a cream-coloured foam (703mg) m.p. 68-700C.
T.l.c. System A(93:7:0.7)Rf0.18.
Example 33 N-(2'-Chloro-4'-formyl[1,1'-biphenyl]-4-yl)-3-[3-(dimethylamino)propyl] -4-methoxvbenzamide hvdrochloride A solution of Example 32 (598mg) in dry 1,4-dioxan (40ml) was treated with activated manganese (IV) oxide (803mg) and heated at reflux under nitrogen for 4h. The reaction mixture was then filtered when cold, and the filter pad was washed with hot ethanol (1 litre). The filtrate was then evaporated in vacuo and the residue purified by SPC eluting with System A (95:5:0.5) to give the free base of the title compound as a gum (389mg) which was dissolved in minimum ethyl acetate, and treated with ethereal HCI to pHi to give the title compound as a cream solid (321mg) m.p. 160-1620C.
Analysis Found: C,63.2; H,5.9; N,5.3. Cl,14.3 C26H27ClN2O3.HCl 0.39 H2O requires C,63.2; H,5.9; N,5.7; Cl,14.3% Water Assay Found 1.43% H2O w/w= 0.39 mol H,O.
Example 34 3-[3-(Dimethylamino)propyl]-4-methoxy-N-[4'-(methoxymethyl)-2'-methyl [1,1'-biphenyl]-4-yl]benzamide Intermediate 30 (263mg), Intermediate 34 (150mg), tetrakis(triphenylphosphine) palladium (0) (50mg), aqueous sodium carbonate (1N;2ml) and DME (8ml) was reflux under nitrogen for 4h. The mixture was added to water (50ml) and extracted with dichloromethane (3x50ml). The dried extract was evaporated and the residue was purified by FCC eluting with System A (240:10:1) to give the title compound as a colourless gum (90mg).
T.l.c. System A (90:10:1), Rf0.6.
n.m.r. (250MHz, CDCI3) 6 1.82 (2H, m), 2.26 (6H, s), 2.3 (3H, s), 2.35 (2H, t), 2.7 (2H, t), 3.43 (3H, s), 3.89 (3H, s), 4.49 (2H, s), 6.92 (1H, d), 7.2-7.26 (3H, dd + d + d), 7.32 (2H, 1/2 AABB'), 7.67-7.81 (4H, dd + d + 1/2 AA'BB'), 7.9 (1H, br.s).
Example 35 3-[3-(Dimethylamino)propyl]-N-(4'-hydroxy-2'-methyl[1,1'-biphenyl]-4-yl) -4-methoxvbenzamide hydrochloride Thionyl chloride (3ml) was added to the hydrochloride salt of Intermediate 2 (0.634g) and the mixture stirred at reflux for 5 min. When cool, the solution was evaporated, then co-evaporated with toluene (2x10ml). A portion of the residue (0.534g) was added portionwise over 40 min to.a stirred mixture of Intermediate 37 in dry pyridine (6.6ml) (ice-salt cooling) under nitrogen. The mixture was stirred at room temperature for 35 min, then at 900C for 90 min. Further dry pyridine (3ml) was added during this time.
When cool, aqueous sodium bicarbonate (8%, 20ml) was added portionwise and the mixture evaporated. The residue was treated with refluxing ethanol (140ml) and adsorbed onto silica gel (Merck 7734, 12ml). The product was purified from a plug of this silica gel by SPC and eluting with System A (239:10:1 to 1857:130:13) to yield the free base of the title compound as a pale cream solid (0.581g). A portion of this (0.400g) was dissolved in the minimum quantity of refluxing ethanol and treated with ethereal hydrogen chloride to yield the title compound as a white powdery solid,(0.241g).
T.l.c. System A (114:10:1) Rf0.17.
Analysis Found: C,67.9; H,7.0; N,6.0; Cl,7.8 C26H30N2O3.HCl.0.22H2O requires: C,68.0; H,6.9; N,6.1; Cl,7.8% Water assay Found 0.88% H2O w/w= 0.22molH20.
Similarly prepared was: Example 36 N-T4'-T(Acetvlamino)methvllrl . I'-biDhenvll-4-vll-3-r3-(dimethvlamino) propyl]-4-methoxybenzamide as a cream-coloured solid (851mg) m.p. 225-2260C.
Analysis Found: C,72.8; H,7.2; N,9.0.
C2gH33N3O3 0.027 H20 requires C,73.1; H,7.2; N,9.1%.
Water Assay Found: 0.10% H2O w/w = 0.027mol H2O From the hydrochloride salt of Intermediate 2 (0.87g) and Intermediate 40 (0.78g).
Purification by SPC eluting with System A (93:7:0.7) afforded the title compound.
Example 37 4'-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amino]-2'-methyl[1,1'-biphenyl] -4-ol acetate (ester) citrate Acetic anhydride (1.00ml) was added at 0 under nitrogen to a stirred solution of the product of Example 48 (280mg) in pyridine (lOml), and the solution stored at 0 for three days. The solution was evaporated and the residue treated with aqueous saturated sodium bicarbonate (30ml). The mixture was extracted with ethyl acetate (6x50ml) and the combined, dried organic extracts were evaporated to give the crude free base (221mg). A portion of the crude free base (195mg) was treated with citric acid monohydrate (120mg), followed by ethanol (3ml) and stirred at reflux to effect solution.
On cooling, the title compound crystallised as fine white crystals (74mg).
T.l.c. System A (89:10:1), Rf 0.39.
Analysis Found: C,60.7; H,6.2; N,4.1; C28H32N2O4.C6O7. 1.02H2O requires: C,60.8; H,6.3; N,4.2% Water assay Found: H2O, 2.75%w/w = 1.02 H2O Example 38 N-(2'-Chloro-4'-methyl[1,1'-biphenyl]-4-yl)-3-[3-(dimethylamino)propyl]-4 methoxvbenzamide A hot solution of Intermediate 41 (250mg) and Intermediate 20 (575mg) was treated according to the method of Example 32. Purification by SPC eluting with System A (93:7:0.7), gave the title compound as a cream-coloured foam (283mg) m.p. 63-660C T.l.c. System A (85:15:1.5) Rf0.49.
Similarly prepared were: Example 39 N-(4'-Acetyl-2-methyl[1,1'-biphenyl]-4-yl)-3-[3-(dimethylamino)propyl] -4-methoxybenzamide hydrochloride as a white solid (488mg) m.p 264-2660C.
Analysis Found: C,- 69.2; H, 6.8; N, 5.6; Cl, 7.6.
C28H32N2O3.HCl.0.06 H2O requires C, 69.7; H, 6.9; N, 5.8; Cl, 7.35% Assay Found : 0.25% w/w H2O=0.06 mol 1120.
From Intermediate 45 (700mg) and Intermediate 46 (0.28g). Purification by SPC eluting with System A (890:100:10) afforded the free base ofthe title compound (0.56g) as an orange/yellow gum. A solution of this gum (530mg) in ethyl acetate (10 ml) was treated with ethereal hydrogen chloride until the acidity was pH1. The solid was filtered off to yield the title compound.
Example 40 3-[3-(Dimethylamino)propyl]-N-(4'-formyl-2'-methyl[1,1'-biphenyl]-4-yl) -4-hvdroxvbenzamide as a light yellow foam (0.31g).
T.l.c. System G (923:70:7) Rf0.32.
Analysis Found: C,73.4; H,6.8; N,6.4.
C26H28N2O3.0.31 H2O.0.05C2H5OH requires C,73.9; H,6.8; N,6.6%.
Water Assay Found: 1.33% w/w H2O=0.31 mol H2O From Intermediate 21 (0.51g) and Intermediate 28 (0.34g). Purification by SPC eluting with a gradient of System G (967:30:3 to 956:40:4) gave a light yellow foam which on drying gave then title compound.
Example 41 3-[3-(Dimethylamino)propyl]-N-[4'-(hydroxymethyl)-2,2'-dimethyl[1,1'-biphenyl]-4-yl] -4-methoxvbenzamide as a cream-coloured foam (1.15g) m.p. 68- 700 Analysis Found: C,73.2; H,7.6; N,5.9.
C28H34N2O3.0.3H2O.0.5 C2H5OH requires: C,73.3; H,8.0; N,5.9%.
Water Assay Found: 1.19% 1120 w/w=0.3mol H20 From Intermediate 47 (1.06g) and Intermediate 45 (1.3g) Purification by SPC eluting with System A (90:10:0.5) afforded the title compound.
Example 42 3-[3-(Dimethylamino)propyl]-N-(4'-formyl-2,2'-dimethyl[1,1'-biphenyl]-4-yl)-4methoxybenzamide A solution of the product of Example 41(1.19g) in dry 1,4-dioxan (12ml), was treated with activated manganese (IV) oxide (1.61g), and heated at reflux under nitrogen for 3h.
When cool, the reaction mixture was filtered, and the filter cake was washed with hot ethanol (2.5 litres). The washings were combined and evaporated in vacuo to give a yellow solid, which was purified by SPC eluting with System A (96:4:0.4) to give the title compound as a yellow solid (0.91g) m.p. 63-660C.
Analysis Found: C,74.4; H,7.1; N,6.0.
C28H32N2O3 0.121120, 0.25 C2H5OH requires C,74.7; H,7.4; N,6.1%.
Water Assay Found: 0.48% H2O w/w=0.12mol H2O Example 43 N-(4'-Acetyl-2'-methyl[1,1'-biphenyl]-4-yl)-3-[3-(dimethylamino)propyl]-4methoxybenzamide The hydrochloride salt of Intermediate 2 (0.15g) was treated with thionyl chloride (4ml) and stirred at reflux for 20 min. When cool, the solution was evaporated and then co-evaporated with toluene (2x 20ml). The residue was treated with Intermediate 49 (137mg), followed by pyridine (5ml) and then stirred at 1100 under nitrogen for 18h.
When cool, aqueous saturated sodium bicarbonate (8%; 50ml) was added and the mixture evaporated. The residue was purified by SPC eluting with System A (97:3:0.3) to give the title compound as a light brown oil. Re-evaporating the sample with ethyl acetate (50ml) transformed the oil into a light brown solid (171 mg), m.p. 110-1 120C.
Analysis Found: C,74.9; H,7.5; N,5.9 28H32N2O3 0.15 H2O requires C,75.2; H,7.3; N,6.
Water Analysis Found: 0.59% w/w H2O= 0.15 mol H2O Example 44 3-T3,(Dimethvlamino)propdl-N-r4'- 1 -hydroxyethvl)-2'-methyl [1, 1.1 '-biphenyll-4-vll-4- methoxvbenzamide a solution of the product of Example 43 (200mg) in ethanol (6ml) was treated with sodium borohydride (34mg) and stirred under nitrogen for 18h at room temperature.
Acetic acid (2 ml) was added, followed by aqueous saturated sodium bicarbonate (6ml), and the mixture partially evaporated. The aqueous residue was extracted with ethyl acetate (3 x 25 ml), and the combined, dried organic extracts were evaporated. The residue was purified by SPC eluting with System A (97:3:0.3) to give the title compound as a cream coloured foam (140mg).
T.l.c. System A (95:5:0.5) Rf0.2 Analysis Found: C,74.5; H,7.8; N,5.9.
28H34N2O3 0.2 CH3CO2C2H5 requires C,74.5; H,7.7; N,6.0% Example 45 3-[3-(Dimethylamino)propyl]-N-[4'-(hydroxymethyl)-2'-methyl[1,1'-biphenyl]-4-yl] -4-METHOXYBENZAMIDE A solution of the free base of the product of Example 3 (500mg) in ethanol (25ml) was added to a pre-reduced suspension of platinum on carbon (5%, 1SOmg) and hydrogenated at room temperature and pressure until uptake ceased. The catalyst was filtered off and evaporated to yield a yellow liquid. The yellow oil was purified by FCC, eluting with System A (923:70:7) to give a cream-coloured foam (0.23g). Further purification by SPC eluting with the same eluent afforded the title compound as a cream foam, (0.20g) m.p 62-650C.
Analysis Found: C,74.35; H,7.5; N,6.0.
C27H32N2O3.0.34H2O requires C,73.9; H,7.5; N,6.4%.
Water Assay Found: 1.40% w/w H2O= 0.34mol 1120.
Example 46 3-[3-(Dimethylamino)propyl]-N-(4'-formyl-2'-methyl[1,1'-biphenyl]-4-yl) -4-methoxvbenzamide. hydrochloride (1:1) 2N Sodium bicarbonate solution (20ml) was added to the ethanedioate (1:1) salt ofthe compound of Example 3 (656mg). The resulting solution was extracted with ethyl acetate (4 x 20ml), the extract dried and evaporated to yield the free base, (288mg).
Ethereal hydrochloric acid (5ml) was added to the free base (288mg), the solid filtered off, washed with ethyl acetate and dried under high vacuum at 600 to give the title compound as a cream-coloured solid (0.09g), m.p. 112-1150.
Analysis Found: C,68.3; H,6.6; N,5.7% C27H30N2O3.HCl.040H2O requires C,68.4; H,6.8; N,5.9% Water assay Found 1.53% w/w H2O = 0.40mol 1120.
Example 47 4'-[[3-[3-(Dimethylamino)propyl]-4-hydroxybenzoyl]amino][1,1'-biphenyl] -4-carboxamide Sodium hydride (741mg, 52% dispersion in oil,) was washed under nitrogen with hexane (3x10ml), treated with dry DMF (8ml) and then ethanethiol (1.18ml, 0.99g) in DMF (8ml) was added dropwise over Smin After ih the free base of Example 10 (0.680g) was added followed by DMF (8ml). The solution was heated at 1500 under nitrogen for 19h.
The cooled dark mixture was evaporated in vacuo, acidified with hydrochloric acid (5N) then basified to pH 8 by the addition of aqueous saturated sodium bicarbonate. The precipitate was filtered off, stirred with refluxing ethanol (1000ml) and filtered to remove insoluble material. The filtrate was adsorbed onto silica gel (Art 9385, 5g) and purified by FCC eluting with System A (37:7:0.7) to give a white powder (125mg) which was recrystallised from hot ethanol (500ml) to give the title compound as a white powder (60mg) T.l.c. System A (37:7:0.7) Rf 0.21.
Analysis Found: C,71.2; H,6.7; N,9.8%.
C25H27N3O30.17C2HOH requires C,71.6; H,6.6; N,9.9%.
Example 48 3-[3-(Dimethvlamino!propvll-N-(4'-hvdroxv-2-methylL F * ,1 '-biphenyllA-vI) 4-methoxvbenzamide A catalytic quantity of tetrakis(triphenylphosphine)palladium (0) (143mg) was added to a degassed refluxing mixture of Intermediate 45 (1.00g), Intermediate 23 (684mg) and sodium carbonate (287mg) in DME (10ml) and water (10ml). The reaction mixture was heated at reflux for 6h, under nitrogen. A further quantity of Intermediate 23 (340mg) was added and the reaction mixture was heated at reflux for a further 6h. The reaction mixture was added to aqueous sodium hydrogen carbonate (1M; 150mi) and extracted with dichloromethane (5x50ml).The combined extracts were dried, filtered and evaporated to give a brown gum (1.82g). The gum was purified by FCC eluting with System A (100:8:1) to give a colourless gum-(696mg), which was dissolved in boiling ethyl acetate (75ml) with a minimum of methanol. The hot solution was filtered, the filtrate was concentrated to (25ml) and the solution allowed to cool to room temperature overnight. The resulting solid was filtered off, washed with ether an dried under vacuum to give the title compound as an off-white crystalline solid (445mg) m.p. 184-186 C Analysis Found: C,73.9; H,7.4; N,6.5.
C26H30N2O3.0.1H2O requires C,74.3; 11,7.2; N,6.7%.
Water analysis indicates 0. iH2O Example 49 3-[3-(Dimethylamino)propyl]-N-[4'-formyl[1,1'-biphenyl]-4-yl)-4-methoxybenzamide maleate (1:1) Activated manganese (IV) oxide (1.89g) was added to a hot solution of the free base of Example 24 (1.67g) in dry 1,4-dioxan (120ml) and the mixture stirred at reflux for 2h.
The cooled suspension was filtered and evaporated. The product was purified by FCC eluting with System A (189:10:1) to give a cream-coloured yellow solid (1.20g). A portion of this (0.30g) was treated with maleic acid (0.13g) and ethanol added in portions until a solution was obtained at reflux. On cooling the title compound crystallized as cream crystals (0.15g), m.p. 1 730C Analysis Found: C,67.4; H,6.0; N,5.0.
C26H28N2O3.C4H4O4 requires C,67.65; H,6.1; N,5.3.
Example 50 3-[3-(Dimethylamino)propyl]-N-[4'-[(hydroxyimino)methyl][1,1'-biphenyl]-4-yl] -4-methoxvbenzamide maleate (1:1) Hydroxylammonium chloride (0.471g) was added to the free base of Example 49 (0.399g), the mixture treated with dry pyridine (7.85ml) and stirred under nitrogen at room temperature for 18h. Sodium bicarbonate solution (8%, 47ml) was added and the mixture stirred under nitrogen for lOmin. The mixture was then evaporated, water (lOOml) was added and the aqueous phase extracted with dichloromethane then chloroform. The combined, dried organic extracts were evaporated to give a white fluffy solid (0.388g). A portion of this (0.348g) was treated with maleic acid (0.145g) and methanol added until a solution was formed at reflux.On cooling, the solution gave the title compound as a pale yellow solid (0.226g) m.p. 187-1890C Analysis Found: C,65.5; H,6.4; N,7.6.
C26H29N2O3.C4H4O4.0.165H2O requires C,65.4; H,6. 1; N,7.6%.
Water Assay 0.54% H2O=0.165 mol H20 Example 51 (E)-3-[3-(Dimethylamino)propyl]-4-methoxy-N-[4'-[(methoxyimino)methyl]-2'-methyl rl.l?-biDhenvll-4-vlIbenzamide hvdrochloride A mixture of the free base of the product of Example 3 (557mg) and O-methylhydroxylamine hydrochloride (756mg) was treated with pyridine (8ml) and stirred at 230 for 18h. Aqueous saturated sodium bicarbonate (5ml) was added and the mixture evaporated. The residue was treated with aqueous saturated sodium chloride (200ml) and extracted with ethyl acetate (5x200ml). The combined, dried organic extracts were evaporated, the residue was stirred in hot ethyl acetate (120ml) for 15 min, then filtered and on cooling, the filtrate deposited the title compound as fine white crystals (175mg).
T.l.c. System A (89:10:1) Rf 0.34.
Analysis Found C,67. 1 5;H,7.0;N,8. 1 ;Cl,7.2.
C28H33N3O3.HCl.0.2H2O requires C,67.3;H,6.9;N.8,4;C1,7. 1% Water assay Found:H2O, 0.73% w/w= 0.2mol Example 52 1,1'-Biphenyl]-4-yl)-3-[3-(dimethylamino)propyl]-4-methoxybenzamide A mixture of Intermediate 30 (600mg), Intermediate 64 (400mg), tetrakis (triphenylphosphine)palladium (O) (100mg), aqueous sodium carbonate (4ml) and DME (16ml) was refluxed under nitrogen for 6h. The mixture was added to water (50ml) and extracted with dichloromethane (3x75ml). The dried extract was evaporated and the residue was purified by FCC eluting with System F (190:10:1) to give the title compound as a white solid (115mg).
T.l.c. System F (90:10:1), Rf0.6 Analysis Found C,74.8; H,7.0; N,6.9; C25H28N2O2.0.6H2O requires C,75.2; H,7.4; N,7.0% Example 53 4'-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amino]-3-methyl[1,1'-biphenyl] -4-methanol. acetate ester A solution ofthe product of Exmaple 45 (120mg) in acetic anhydride (0.5ml) was treated with pyridine (5 drops) and stirred at room temperature for 3h. The soltion was purified by FCC eluting with ethyl acetate:methanol:ammonia (90:10:1) to give the title compound as a colourless gum (1 lOmg).
T.l.c. ethyl acetate:methanol:ammonia (90:10:1), Rf 0.3 Analysis Found C,71.3; H, 7.3; N,5.7; C29H34N204 0.8H,O requires C, 71.2; H, 7.3; N,5.7% Example 54 Methyl 4'-[[3-[3-(dimethylamino)propyl]-4-methoxybenzoyl]amino][1,1'-biphenyl]-4carboxvlate A solution of Intermediate 51 (496mg) in DMF (40ml) was added to a mixture of pre-hydrogenated 5% palladium on carbon (0.25g) in dry THF (20ml) and the stirred suspension hydrogenated at room temperature and pressure for 15 min. The mixture was filtered and the filtrate evaporated to give a cream solid (422mg). A portion (406mg) was crystallised from toluene (50ml) to give a buff powder.The powder and the mother liquors were adsorbed from hot ethanol onto silica gel (Merck 9385) and purified by FCC eluting with System E (57:10:1) to give the title compound as a white solid (302mg) m.p.
188-191.5 .
Analysis Found: C, 72.6; H,6.7; N, 6.2 C27H30N204 requires C,72.6; H,6.8; N, 6.3% Example 55 2-Methoxyethyl 4'-[[3-[3-(dimethylamino)propyl]-4-methoxybenzoyl]amino]-2-methyl [1,1'-biphenyl]-4-carboxylate Portions of 3-[3-(dimethylamino)propyl]-4-methoxybenzoyl chloride hydrochloride (623mg) (prepared from the hydrochloride salt of Intermediate 2 and thionyl chloride) were added to a stirred solution of Intermediate 54 (649mg) in pyridine (10ml) at 0 C under nitrogen over a period of 20min. After 30min at room temperature, the stirred solution was heated to 90 for a further 40min. When cool, aqueous saturated sodium bicarbonate (20ml) was added and the mixture evaporated. The residue was stirred in hot ethanol (30ml) and the mixture adsorbed onto silica gel (Merck 7734, 15ml).Purification by FCC eluting with System A (967:30:3 to 956:40:4) gave the title compound as a yellow liquid (0.79g). The yellow liquid was stirred in hot ethanol and the mixture adsorbed onto silica gel (Merck 7734, 10ml) and further purified by FCC eluting with System A (967:30:3) to give the title compound as a yellow oil (454mg).
T.l.c. System A (956:40:4) Rf0.19 Analysis Found: C,70.3; H,7.1; N,5.65 C30H27N2O5.0.31H2O requires C,70.6; H,7.2; N,5.5% Water Assay Found: H2O, 1.10%w/w = 0.31mol Example 56 2-(Dimethylamino)ethyl 4'-[[3-[3-(dimethylamino)propyl]-4-methoxybenzoyl]amino]-2 methyl[1,1'-biphenyl]-4-carboxylate A stirred mixture of Intermediate 30 (0.8g), Intermediate 55 (0.64g), tetrakis(triphenylphosphine)palladium (0) (0.13g) and anhydrous sodium carbonate (0.356g) in water (25ml) and DME (50ml) under nitrogen, was heated at reflux. After 18h, the solution was cooled and the reaction contents adsorbed onto silica gel [Merck Art. 7734]. Purification by SPC eluting with System A (94:6:0.6) afforded the title compound as a pale yellow oil (0.352g).
Analysis Found C,70.7; H,7.8; N,7.6.
C31H3,N3O4.0.28 H2O requires C,71.2; H,7.6; N,8.0%.
Water assay Found: 0.96% w/w EI20 ~ 0.28mol H2O n.m.r. (DMSO) 6 1.73 (2H,m), 2.19 (6H,s), 2.28 (8H, s & t), 2.4 (3H,s), 2.68 (4H, 2xt), 3.92 (3H,s), 4.42 (2H,t), 7.15 (lH,brs), 7.38-7.46 (3N,m), 7.84-7.96 (6H,m), 10.2 (lH,brs).
Example 57 2,3-Dihydroxypropyl4'-[[3-[3-(dimethylamino)propyl]-4-methoxybenzoyl aminoi-2-methvlF 1.1 '-biphenyl]A-carboxylate A stirred mixture of Intermediate 30 (0.743g) and Intermediate 57 (0.603g), tetrakis(triphenylphosphine)palladium (0) (0.120g) and anhydrous sodium carbonate (0.440g) in water (5ml) and DME (5ml) under nitrogen was heated at reflux. After 5h, the solution was cooled and the reaction contents adsorbed onto silica gel [Merck Art 7734]. Purification by SPC eluting with System A (91:9:0.9) gave a white foam.The foam was re-columned, as before, to give slightly purer product (0.31 g). H.p.l.c. was performed on the foam to give pure title compound (0.210g), m.p. 60-62 C. (decomp.) Analysis Found: C,67.6; H,7.0; N,5.1; C30H36N2O6. 0.34H2O. 0.45CH3CH2OH requires C,67.8; H,7.25; N,5.1% Water assay Found: 1.14%w/w H2O = 0.34mol H2O.
Example 58 (+/-) 2-Methoxy-1-methylethyl 4'-[3-[3-(dimethylamino)propyl]-4-methoxybenzamido] -2-methyl[1,1'-biphenyl]-4-carboxylate A mixture of Intermediate 58 (322mg) and Intermediate 30 (400mg) in DME (lOml) was treated with a solution of sodium carbonate (238mg) in water (5ml), followed by tetrakis (triphenylphosphine)palladium (O) (65mg) and stirred at reflux under nitrogen for 5h. The cooled mixture was evaporated, treated with water (30ml) and extracted with ethyl acetate (5x50ml). The combined, dried organic extracts were evaporated and the residue purified by SPC (Merck 7729) eluting with System A (967:30:3) to give the title compound as a pale brown glass (120mg).
T.l.c. System A (945:50:5), Rf0.16.
Analysis Found C,71.0; H,7.3; N,5.1 C21H38N2O5.0.49H2O requires C,70.6; H,7.45; N.5.3% Water assay found: 1.67% w/w H2O = 0.49 mol H2O.
Example 59 3-[3-(Dimethylamino)propyl]-4-methoxy-N-[3-methyl-4-(3-oxa-1H-isobenzofuran-6-yl) phenyl]benzamide A mixture of Intermediate 59 (220mg), 5-bromo-1(3H)-isobenzofuranone (150mg), palladium acetate (5mg), tri(orthotolyl)phosphine (15mg), triethylamine (imi) and DMF (2ml) was reflux (100 ) under nitrogen for 4h. The solution was added to water (25ml) and extracted with dichloromethane (3x50ml). The dried extract was evaporated and the residue was purified on a column of silica eluting with ethyl acetate:methanol:ammonia (190:10:1) to give the title compound as an orange foam (245mg).
T.l.c. ethyl acetate:methanol:ammonia (190:10:1) Rf 0.2 Analysis Found: C,70.5; H,6.5; N,5.7; C28H30N2O4.H2O requires C,70.6; H,6.7; N,5.9% Example 60 2-Methoxyethyl 4-[[3-[3-(dimethylamino)propyl]-4-methoxybenzoyl]amino]-3-methoxy -2-methvl[l .1 '-biphenyl]A-carboxylate A mixture of Intermediate 59 (150mg), Intermediate 60 (150mg), palladium acetate (5mg), tri(orthotolyl)phosphine (15mg), triethylamine (imi) and DMF (2ml) was heated at 100 for 5h under nitrogen. The mixture was added to water (30ml) and extracted with ethyl acetate (3x50ml).The dried extract was evaporated and the residue was purified on a column of silica eluting with System F (190:10:1) to give the title compound as a yellow gum (94mg).
T.l.c. System F (90:10:1) Rf 0.4 Analysis Found: C,65.8; H.7.3; N,5.0; C31H38N2O62H2.O requires C,65.3; H,7.4; N,4.9% Example 61 N-[4-(3-Oxa-1H-isobenzofuran-6-yl)phenyl]-3-[3-(dimethylamino)propyl]-4methoxvbenzamide A mixture of Intermediate 30 (500mg), 5-bromo-1(3H)-isobenzofuranone (320mg), tetrakis(tiphenylphosphine)palladium (0) (100mg), aqueous sodium carbonate (4ml) and DME (15ml) was reflux under nitrogen for 2h. The resulting mixture was treated with brine (50ml) and extracted with dichloromethane (3x70ml). The dried extract was evaporated and the residue was purified by chromatography eluting with System F (190:10:1) followed by (90:10:1) to give the title compound as a white solid (370mg) T.1.c.System F (190:10:1) Rf 0.4 Analysis Found C,72.i; H,6.4; N,6.2 C27H28N2O4.0.3H2O requires C,72. 1; H,6.2; N.6.2% Example 62 (+/-)-[4'-[[3-[3-(Dimethylamino)propyl]-4-methxybenzoyl]amino]-3-methyl[1,1'biphenyl]-4-yl]methyl 2-methoxypropanoate DMF (1drop) was added to a solution of (+)-2-methoxypropanoic acid (52mg) and oxalyl chloride (63mg) in dichloromethane (2ml). The solution was stirred until effervescence ceased (30min) and was added dropwise to a solution of the product of Example 45 (200mg) in dichloromethane (5ml) under nitrogen. The resulting suspension was evaporated and the residue was triturated with ether to leave a solid.The solid in dichloromethane (5ml) and triethylamine (2ml) was treated dropwise with a solution of the acid chloride (prepared as above) in dichloromethane (2ml) and stirred for 1 hour.
The mixture was added to aqueous sodium carbonate (1M; 20ml) and extracted with dichloromethane (3x50ml). The dried extract was evaporated and the residue was purified by FCC eluting with System F (190:10:1) to give the title compound as a colourless gum (67mg).
T.l.c. System F (90:10:1) Rf 0.6 n.m.r. 6 1.45 (3H,d), 1.80 (2H,m), 2.25 (6H,s), 2.30 (3H,s), 2.35(2H,m), 2.7(2H,m), 3.41 (3H, s), 3.9 (3H,s), 3.95 (lH,q), 5.2 (2H, s), 6.92 (1H,d), 7.22-7.26 ( > 3H,m), 7.32 (2H, 1/2 AA' BB'), 7.68-7.73 (311,m), 7.77 (lH,dd), 7.87 (lH,br.s).
Example 63 4'-[[3-[3-(Dimethylamino)propyl]-4-methoxybenzoyl]amino]-2-methyl-N-(methylsulfonyl) r1.1 '-biphenvll-4-carboxamide A mixture of Intermediate 30 (250mg), Intermediate 61 (200mg), palladium (II) acetate (5mg), tri(orthotolyl)phosphine (15mg), DMF (2ml) and triethylamine (1 ml) was reflux under nitrogen for 3h. The cooled mixture was treated with water (30ml) and extracted with dichloromethane (3x50ml). The dried extract was evaporated and the residue was purified by FCC eluting with System F (90:10:1) to give a pale yellow solid. The solid was triturated with hot methanol (lOml) to leave the title compound as a white powder (95mg) m.p. 253-254".
T.l.c. System F (90:10:1) Rf 0.2.
Example 64 N-[4-(4H-1,3-Benzodioxin-7-yl)phenyl]-3-[3-(dimethylamino)propyl]-4methoxvbenzamide A mixture of Intermediate 30 (150mg), Intermediate 63 (100mg),l tetrakis (triphenylphosphine)palladium (O) (30mg), aqueous sodium carbonate (2ml) and DME (5ml) was refluxed under nitrogen for lh. The cooled mixture was treated with brine (50ml) and extracted with dichloromethane (3x70ml). The dried extract was evaporated and the residue was purified by FCC eluting with System F (190:10:1) to give the title compound as a white solid (62mg).
T.l.c. SystemF(90:10:1) Rf 0.5 Analysis Found: C,70.1; H,6.6; N,6.1; C27H30N2O4.H2O requires C,69.8; H,6.9; N,6.0% Example 65 N-[4-(1,3-Benzodioxol-5-yl)phenyl]-3-[3-(dimethylamino)propyl]-4-methoxybenzamide A mixture of Intermediate 30 (300mg), 5-bromo-1,3-benzodioxole (200mg), tetrakis(triphenylphosphine)palladium (O) (50mg), aqueous sodium carbonate (2ml) and DME (8ml) was reflux under nitrogen for 6h. The mixture was added to water (30ml) and extracted with dichloromethane (3x50ml). The dried extract was evaporated to give a white solid which was recrystallised from isopropanol (20ml) to give the title compound as a white powder (185mg). m.p. 190-192 .
Analysis Found C,70.0; H,6.2; N,5.8 C26H28N2O4-0.7H2O requires C,70.2; H,6.6; N.6.3% Example 66 3-[3-(Dimethylamino)propyl]-4-methoxy-N-[2'-methyl-4-(1,3-oxathiolan-2-yl)[1,1' biphenyliA-vlibenzamide A mixture of the product of Example 46 (500mg) and 2-mercaptoethanol (0.073ml) in dichloromethane (20ml), under nitrogen was cooled (0 ) and treated wth boron trifluoride etherate (0.026ml). Stirring was maintained at 0 for 1h, then at 200 for 18h.
The mixture was then washed with 8% sodium bicarbonate (30ml), and the aqueous layer was extracted with dichloromethane (20ml). The combined dried extracts were evaporated to give a pale yellow foam which was purified by FCC eluting with System A (150:8:1) to give the title compound as a colourless foam (173mg).
T.l.c. System A (100:8:1) Rf 0.47 Assay Found: C,69.75; H,6.9; N,5.55; C29H34N2O3S.0.45H2O requires C,69.85; H,7,05; N,5.6% Water Determination Found 1.56% w/w =0.45 mol% H2O Also isolated from the columns was the corresponding bis-(hydroxyethyl sulphide).
Example 67 3-[3-(Dimethylamino)propyl]-N-[4'-(1,3-dioxolan-2-yl)-2'-methyl[1,1'-biphenyl]-4-yl]-4methoxvbenzamide The free base of Example 46 (460mg) was dissolved in toluene (20ml) and p-toluenesulphonic acid (224mg) and ethylene glycol (0.12ml) was added. The mixture was then heated to reflux in the presence of molecular sieves for 18h. Further ethylene glycol (2ml) was added, and heating maintained for a further 2h. The cooled mixture was partitioned between 8% sodium bicarbonate solution (40ml) and ethyl acetate (2x40ml).
The dried extracts were evaporated to give a pale yellow oil which was purified by FCC eluting with System A (200:8:1) to give the title compound as a colourless solid (254mg).
T.l.c. System A (100:8:1) Rf 0.51.
Assay Found C,72.3; H,7.3; N,5.8; C29H34N4O2.0.43H2O requires C,72.2; H.7.3; N,5.8% Water Determination 1.63% w/w =0.43 mol H20 Example 68 3-[3-(Dimethylamino)propyl]-N-[4'-(1H-imidazol-1-ylmethyl)[1,1'-biphenyl]-4-yl]-4methoxvbenzamide The hydrochloride salt of Intermediate 2 (0.154g) and Intermediate 66 (0.1 4g) was treated according to the method of Example 35. Purification by SPC eluting with System A (95:5:0.5) afforded the title compound. as a cream-coloured solid (195mg) m.p.
240-241 C.
T.l.c. System A (95:5:0.5) Rf0.15 Example 69 [N-[3-(Dimethylamino)propyl]-4-methoxyphenyl]-2'-methyl-4-(5-methyl-1,2,4-oxadiazol3-yl)[1,1'-biphenyl]-4-carboxamide To a stirred solution of Intermediate 68 (141mg) in dry pyridine (4ml) was added thionyl chloride (0.04ml). The mixture was stirred for ih at 20 and then a solution of Intermediate 27 (100mg) in dry pyridine (2ml) was added. The mixture was then stirred at 20 for 20h. and 2N sodium carbonate (50ml) added. The mixture was extracted with ethyl acetate (2x50ml), the combined extracts dried and, after filtration, were evaporated to give an oil which was purified by FCC eluting with System A (100:8:1) to give the title compound as a beige solid (71mg) T.l.c.System A (100:8:1) Rf 0.28 Assay Found: C,7.6; H,6.7; N, 11.25; C29H32N4O3 requires C,71.9; H,6.65; N,11.55% Example 70 3-[3-(Dimethylamino)propyl]-4-methoxy-N-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3yl)[1,1'-biphenyl]-4-yl]benzamide A mixture of Intermediate 67 (322mg) and Intermediate 30 (500mg) in water (10ml) and glyme (i0ml) containing sodium carbonate (444mg) and tetrakis (triphenylphosphine)palladium (0) (3Omg) was heated to reflux under nitrogen for 1 8h.
The mixture was allowed to cool and silica gel (Merck 9385, 15g) was added, and the solvents evaporated. The residue was chromatographed eluting with System A (200:8:1 to give the title compound as a colourless oil which crystallised on standing (363mg) m.p.
163-165 C.
Assay Found C,71.75; H,6.75; N,11.35; C29H32NO3 requires C, 71.9; H,6.65; N,11.55% Similarly prepared was: Example 71 3-[3-(Dimethylamino)propyl]-4-methoxy-N-[2'-methyl-4'-(3-methyl-1,2,4-oxadiazol-5-yl) [1,1'-biphenyl]-4-yl]benzamide as a cream-coloured solid (159mg) m.p. 166-167 C.
Assay Found: C,71.75; H, 6.75; N,11.3: C29H32N4O3 requires C,71.9; H,6.65; N,11.55% From a mixture of Intermediate 30 (385mg) and Intermediate 69 (248mg) in water (lOml) and glyme (10ml) containing sodium carbonate (343mg) and tetrakis(triphenylphosphine) palladium (0) (23mg).

Claims (2)

Claims
1. Compounds of the general formula (I) :
or a physiologically acceptable salt or solvate thereof, in which R1 represents a hydrogen atom or a halogen atom or a C1alkyl or C1 6alkoxy group; R2 and R3, which may be the same or different, each independently represent a hydrogen atom or a halogen atom, or C1 6alkyl, hydroxyC1 6alkyl, C1 6alkoxy, hydroxy, -CF3, -CH, -NO2, -CO2R10, -COR6, -SR6, -SOR6, -SO2R6, -CR6=NOR7, -CONR6R7, -CONR6SO2R7, -CONR6(CH2)mCO2R7, -CONR6(CH2)mOC1-4alkyl, -SO2NR6R7, -OC(O)NR6R7, -(CH2)nNR8R9, -(CH2)nOC(O)C1-4alkyl (optionally substituted by a C1 6alkoxy group), or C1-4alkoxyalkyl (optionally substituted by a C1-4alkoxy or hydroxy group); or R represents a 1,2,4-oxadiazol-3-yk, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2yl, 1,2,5-oxadiazol-3-yl, imidazol-1-ylmethyl, dioxolan or thioxolan group, each of which may be optionally substituted by a C1-3alkyl group; or, when R2 and R3 are attached to adjacent carbon atoms, they may form a 5or 6-membered saturated fused ring which contains one or two oxygen atoms and which may be optionally substituted by an oxo group; R4 and R5, which may be the same or different, each independently represent a hydrogen atom or a halogen atom, or a hydroxy, C16alkoxy or C1 6alkyl group; R6, R7 and R8 which may be the same or different, each independently represent a hydrogen atom or a C1 6alkyl group; or -NR6R7 forms a saturated heterocyclic ring which has 5 or 6 ring members which, when there are 6 ring members, may optionally contain in the ring one oxygen or sulphur atom; R9 represents a hydrogen atom or a C1-6alkyl, -COR or -S02R14 group; or -NR8R9 forms a saturated heterocyclic ring which has 5 or 6 ring members, may optionally be substituted by an oxo group and, when there are 6 ring members, may optionally contain in the ring one oxygen or sulphur atom; R10 represents a hydrogen atom or a C1 6alkyl group optionally substituted by one or two substituents selected from C1 6alkyl, C1 6alkoxy, hydroxy or -NR6R7; R11 and R12, which may be the same or different, each independently represent a hydrogen atom or a C1 6alkyl group; ; R13 represents a hydrogen atom or a group selected from C1 alkyl, C1-6alkoxy or a C1-4alkoxyalkyl group; R14 represents a C1 6alkyl or phenyl group; X represents -CONH-, -NHCO-, -CH2NH- or -NHCH2-; m represents an integer from 1 to 3; n represents zero or an integer from I to 3; and p represents an integer from 2 to 4.
2. Compounds as claimed in Claim 1 for use in therapy.
GB9305468A 1993-03-17 1993-03-17 Aniline and benzanilide derivatives Withdrawn GB2276161A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9305468A GB2276161A (en) 1993-03-17 1993-03-17 Aniline and benzanilide derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9305468A GB2276161A (en) 1993-03-17 1993-03-17 Aniline and benzanilide derivatives

Publications (2)

Publication Number Publication Date
GB9305468D0 GB9305468D0 (en) 1993-05-05
GB2276161A true GB2276161A (en) 1994-09-21

Family

ID=10732199

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9305468A Withdrawn GB2276161A (en) 1993-03-17 1993-03-17 Aniline and benzanilide derivatives

Country Status (1)

Country Link
GB (1) GB2276161A (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026328A1 (en) * 1994-03-26 1995-10-05 Smithkline Beecham Plc Biphenyl derivatives as 5ht1d antagonists
EP0757982A1 (en) * 1995-08-08 1997-02-12 Roussel Uclaf Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them
WO1997007120A1 (en) * 1995-08-11 1997-02-27 Smithkline Beecham Plc Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists
US6420396B1 (en) * 1998-12-16 2002-07-16 Beiersdorf Ag Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6677360B2 (en) 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
WO2004096771A1 (en) * 2003-04-29 2004-11-11 Glaxo Group Limited Biaryl compounds having activity at the 5ht5a receptor
US7091228B2 (en) 2003-05-09 2006-08-15 Bayer Pharmaceuticals Corporation Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
US7125898B2 (en) 2002-02-12 2006-10-24 Smithkline Beecham Corporation Nicotinamide derivatives useful as p38 inhibitors.
US7151118B2 (en) 2001-10-17 2006-12-19 Glaxo Group Limited Biphenylcarboxylic amide derivatives as p38-kinase inhibitors
JP2006528641A (en) * 2003-07-23 2006-12-21 シンタ ファーマシューティカルズ コーポレーション Compounds for inflammation and immune related uses
US7166623B2 (en) 2001-10-17 2007-01-23 Glaxo Group Limited 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7166597B2 (en) 2000-08-22 2007-01-23 Glaxo Group Limited Fused pyrazole derivatives being protein kinase inhibitors
US7183297B2 (en) 2001-10-17 2007-02-27 Glaxo Group Limited Biphenyl-derivatives as p38-kinase inhibitors
US7208629B2 (en) 2001-10-17 2007-04-24 Glaxo Group Limited 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7271289B2 (en) 2003-04-09 2007-09-18 Smithkline Beecham Corporation Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7384963B2 (en) 2001-10-17 2008-06-10 Glaxo Group Limited 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase
US7396843B2 (en) 2001-10-17 2008-07-08 Glaxo Group Limited 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7432289B2 (en) 2001-10-17 2008-10-07 Glaxo Group Limited 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors
US7572790B2 (en) 2003-04-09 2009-08-11 Smithkline Beecham Corporation Biphenyl carboxylic amide p38 kinase inhibitors
US7615651B2 (en) 2006-11-13 2009-11-10 Pfizer Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
US7626055B2 (en) 2003-04-09 2009-12-01 Smithkline Beecham Corporation Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors
US7642276B2 (en) 2002-07-31 2010-01-05 Smithkline Beecham Corporation Fused heteroaryl derivatives for use as P38 kinase inhibitors
EP2226320A1 (en) * 2007-12-26 2010-09-08 Eisai R&D Management Co., Ltd. Process for production of heterocycle-substituted pyridine derivative
US7838540B2 (en) 2003-08-11 2010-11-23 Glaxosmithkline Llc 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors
JP2011502983A (en) * 2007-11-01 2011-01-27 アキュセラ インコーポレイテッド Amine derivative compounds for the treatment of eye diseases and disorders
US8202999B2 (en) 2005-01-07 2012-06-19 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
JP2013541505A (en) * 2010-08-11 2013-11-14 フィラデルフィア ヘルス アンド エデュケイション コーポレイション ドゥーイング ビジネス アズ ドレクセル ユニバーシティー カレッジ オブ メディシン Novel D3 dopamine receptor agonists for treating dyskinesia in Parkinson's disease
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
WO2022050385A1 (en) * 2020-09-07 2022-03-10 大日本住友製薬株式会社 Phenol derivative

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026328A1 (en) * 1994-03-26 1995-10-05 Smithkline Beecham Plc Biphenyl derivatives as 5ht1d antagonists
EP0757982A1 (en) * 1995-08-08 1997-02-12 Roussel Uclaf Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them
FR2737721A1 (en) * 1995-08-08 1997-02-14 Roussel Uclaf NOVEL BIPHENYL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US5827887A (en) * 1995-08-08 1998-10-27 Roussel Uclaf Biphenyl compounds
WO1997007120A1 (en) * 1995-08-11 1997-02-27 Smithkline Beecham Plc Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists
US5972935A (en) * 1995-08-11 1999-10-26 Smithkline Beecham P.L.C. Biphenyl(thio)amide and bipennylethan(thi) one derivatives, their preparation and their use as 5-HT1D receptor antagonists
US7094911B2 (en) 1998-12-16 2006-08-22 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6420396B1 (en) * 1998-12-16 2002-07-16 Beiersdorf Ag Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6677360B2 (en) 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
US7166597B2 (en) 2000-08-22 2007-01-23 Glaxo Group Limited Fused pyrazole derivatives being protein kinase inhibitors
US7151118B2 (en) 2001-10-17 2006-12-19 Glaxo Group Limited Biphenylcarboxylic amide derivatives as p38-kinase inhibitors
US7183297B2 (en) 2001-10-17 2007-02-27 Glaxo Group Limited Biphenyl-derivatives as p38-kinase inhibitors
US7432289B2 (en) 2001-10-17 2008-10-07 Glaxo Group Limited 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors
US7396843B2 (en) 2001-10-17 2008-07-08 Glaxo Group Limited 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7166623B2 (en) 2001-10-17 2007-01-23 Glaxo Group Limited 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7384963B2 (en) 2001-10-17 2008-06-10 Glaxo Group Limited 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase
US7208629B2 (en) 2001-10-17 2007-04-24 Glaxo Group Limited 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7125898B2 (en) 2002-02-12 2006-10-24 Smithkline Beecham Corporation Nicotinamide derivatives useful as p38 inhibitors.
US8575204B2 (en) 2002-02-12 2013-11-05 Glaxosmithkline Llc Nicotinamide derivates useful as P38 inhibitors
US8252818B2 (en) 2002-02-12 2012-08-28 Glaxosmithkline Llc Nicotinamide derivatives useful as P38 inhibitors
US7709506B2 (en) 2002-02-12 2010-05-04 Glaxosmithkline Llc Nicotinamide derivatives useful as p38 inhibitors
US7514456B2 (en) 2002-02-12 2009-04-07 Smithkline Beecham Corporation Nicotinamide derivatives useful as p38 inhibitors
US7642276B2 (en) 2002-07-31 2010-01-05 Smithkline Beecham Corporation Fused heteroaryl derivatives for use as P38 kinase inhibitors
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7572790B2 (en) 2003-04-09 2009-08-11 Smithkline Beecham Corporation Biphenyl carboxylic amide p38 kinase inhibitors
US7271289B2 (en) 2003-04-09 2007-09-18 Smithkline Beecham Corporation Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
US7626055B2 (en) 2003-04-09 2009-12-01 Smithkline Beecham Corporation Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors
WO2004096771A1 (en) * 2003-04-29 2004-11-11 Glaxo Group Limited Biaryl compounds having activity at the 5ht5a receptor
US7968576B2 (en) 2003-05-09 2011-06-28 Smith Roger A Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
US7091228B2 (en) 2003-05-09 2006-08-15 Bayer Pharmaceuticals Corporation Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
US7423156B2 (en) 2003-05-09 2008-09-09 Bayer Pharmaceuticals Corporation Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
US8013166B2 (en) 2003-05-09 2011-09-06 Bayer Healthcare Llc Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
JP2012025751A (en) * 2003-07-23 2012-02-09 Synta Pharmaceuticals Corp Compound for inflammation and immune-related use
JP2011252014A (en) * 2003-07-23 2011-12-15 Synta Pharmaceuticals Corp Method for modulating calcium ion-release-activated calcium ion channel
JP2006528641A (en) * 2003-07-23 2006-12-21 シンタ ファーマシューティカルズ コーポレーション Compounds for inflammation and immune related uses
JP2007501186A (en) * 2003-07-23 2007-01-25 シンタ ファーマシューティカルズ コーポレーション CRAC ion channel modulation method
US7838540B2 (en) 2003-08-11 2010-11-23 Glaxosmithkline Llc 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors
US8592486B2 (en) 2005-01-07 2013-11-26 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8202999B2 (en) 2005-01-07 2012-06-19 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US7615651B2 (en) 2006-11-13 2009-11-10 Pfizer Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
JP2011502983A (en) * 2007-11-01 2011-01-27 アキュセラ インコーポレイテッド Amine derivative compounds for the treatment of eye diseases and disorders
EP2226320A4 (en) * 2007-12-26 2012-07-11 Eisai R&D Man Co Ltd Process for production of heterocycle-substituted pyridine derivative
US8410277B2 (en) 2007-12-26 2013-04-02 Eisai R&D Managment Co., Ltd. Method for manufacturing heterocycle substituted pyridine derivatives
EP2226320A1 (en) * 2007-12-26 2010-09-08 Eisai R&D Management Co., Ltd. Process for production of heterocycle-substituted pyridine derivative
JP2013541505A (en) * 2010-08-11 2013-11-14 フィラデルフィア ヘルス アンド エデュケイション コーポレイション ドゥーイング ビジネス アズ ドレクセル ユニバーシティー カレッジ オブ メディシン Novel D3 dopamine receptor agonists for treating dyskinesia in Parkinson's disease
US9675565B2 (en) 2010-08-11 2017-06-13 Drexel University D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
US10543180B2 (en) 2010-08-11 2020-01-28 Drexel University D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
US11266612B2 (en) 2010-08-11 2022-03-08 Drexel University D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US9266873B2 (en) 2011-09-30 2016-02-23 Asana Biosciences, Llc Pyridine derivatives
US9371316B2 (en) 2011-09-30 2016-06-21 Asana Biosciences, Llc Pyridine derivatives
US9533981B2 (en) 2011-09-30 2017-01-03 Asana Biosciences, Llc Pyridine derivatives
WO2022050385A1 (en) * 2020-09-07 2022-03-10 大日本住友製薬株式会社 Phenol derivative

Also Published As

Publication number Publication date
GB9305468D0 (en) 1993-05-05

Similar Documents

Publication Publication Date Title
GB2276161A (en) Aniline and benzanilide derivatives
EP0533267A1 (en) Benzanilide derivatives as 5-HT1D antagonists
JP3255421B2 (en) Substituted oximes, hydrazones and olefins as neurokinin antagonists
AU606087B2 (en) 3,4-dihydro-3-phenyl-2H-1-benzopyran derivatives
US7538241B2 (en) Hsp90 family protein inhibitors
FI62529C (en) FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA ETNOLAMINDERIVAT
EP0533266A1 (en) Benzanilide derivatives as 5-HT1D antagonists
EP1642880B1 (en) Hsp90 family protein inhibitors
EA006430B1 (en) Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method and the pharmaceutical compositions containing same
US6762176B1 (en) 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them
GB2273930A (en) Benzanilide derivatives
WO2002022556A1 (en) Novel amide derivatives and medicinal use thereof ugs
JPH04230348A (en) Substituted aminoalkylbiphenyl derivative
TWI250152B (en) N,N-substituted cyclic amine compounds used as calcium antagonizer
US5239084A (en) Substituted aminoalkyl biphenyl compounds
NO852809L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINOPHENOLD DERIVATIVES.
JPH08502243A (en) 2,5-Diaryltetrahydro-thiophenes, -furans and analogues for the treatment of inflammatory and immune disorders
GB2276165A (en) Aniline and benzanilide compounds.
US4418065A (en) Halophenyl-pyridyl-allylamine derivatives and use
US4410548A (en) Propanolamine derivatives
US20080070951A1 (en) Non-Nucleotide Reverse Transcriptase Inhibitors
EP0000322B1 (en) Compounds having an anti-depressive or tranquilizing activity, pharmaceutical compositions containing them, and processes and intermediates for their preparation
CA1056834A (en) 3-(4-bromophenyl)-n-methyl-3-(3-pyridyl)-allylamine
GB2276164A (en) Aniline and benzanilide derivatives
US5179092A (en) Compound effective as cerebral insufficiency improver

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)